

=> fil wpix

FILE 'WPIX' ENTERED AT 12:47:41 ON 27 MAY 2004
 COPYRIGHT (C) 2004 THOMSON DERWENT

FILE LAST UPDATED: 25 MAY 2004 <20040525/UP>
 MOST RECENT DERWENT UPDATE: 200433 <200433/DW>
 DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
 PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
<http://thomsonderwent.com/coverage/latestupdates/> <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER
 GUIDES, PLEASE VISIT:
<http://thomsonderwent.com/support/userguides/> <<<

>>> NEW! FAST-ALERTING ACCESS TO NEWLY-PUBLISHED PATENT
 DOCUMENTATION NOW AVAILABLE IN DERWENT WORLD PATENTS INDEX
 FIRST VIEW - FILE WPIFV. FREE CONNECT HOUR UNTIL 1 MAY 2004.
 FOR FURTHER DETAILS: <http://www.thomsonderwent.com/dwpifv> <<<

>>> NEW! IMPROVE YOUR LITIGATION CHECKING AND INFRINGEMENT
 MONITORING WITH LITALERT. FIRST ACCESS TO RECORDS OF IP
 LAWSUITS FILED IN THE 94 US DISTRICT COURTS SINCE 1973.
 FOR FURTHER DETAILS:
<http://www.thomsonscientific.com/litalert> <<<

>>> THE DISPLAY LAYOUT HAS BEEN CHANGED TO ACCOMMODATE THE
 NEW FORMAT GERMAN PATENT APPLICATION AND PUBLICATION
 NUMBERS. SEE ALSO:
<http://www.stn-international.de/archive/stnews/news0104.pdf> <<<

>>> SINCE THE FILE HAD NOT BEEN UPDATED BETWEEN APRIL 12-16
 THERE WAS NO WEEKLY SDI RUN <<<

=> d que l100

L95	485	SEA	FILE=WPIX	ABB=ON	PLU=ON	A61K031-69/IPC
L96	1525	SEA	FILE=WPIX	ABB=ON	PLU=ON	(B05-B01A OR C05-B01A)/MC
L97	1861	SEA	FILE=WPIX	ABB=ON	PLU=ON	L95 OR L96
L98	6803	SEA	FILE=WPIX	ABB=ON	PLU=ON	(B12-M03 OR C12-M03)/MC
L99	14	SEA	FILE=WPIX	ABB=ON	PLU=ON	L97 AND L98
L100	1	SEA	FILE=WPIX	ABB=ON	PLU=ON	L99 AND MICROEMULSION/TI,TT

=> d l100 iall abeq tech abex

L100 ANSWER 1 OF 1 WPIX COPYRIGHT 2004 THOMSON DERWENT on STN
 ACCESSION NUMBER: 1993-351328 [44] WPIX
 DOC. NO. CPI: C1993-155866
 TITLE: Therapeutic or diagnostic compsn. targets specific cells
 - by using specific ligand associated with
 lipoprotein(s), **microemulsion** particles,
 liposome(s) or micelles containing the active component.
 DERWENT CLASS: B01 B04 B07 C03 C07
 INVENTOR(S): KINNUNEN, P K J
 PATENT ASSIGNEE(S): (KINN-I) KINNUNEN P K J

COUNTRY COUNT: 43

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN	IPC
WO 9320800	A1	19931028	(199344)*	EN	19	A61K009-127	
RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL OA PT SE							
W: AT AU BB BG BR CA CH CZ DE DK ES FI GB HU JP KP KR LK LU MG MN MW							
NL NO NZ PL PT RO RU SD SE SK UA US VN							
AU 9338925	A	19931118	(199410)			A61K009-127	
EP 634926	A1	19950125	(199508)	EN		A61K009-127	
R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE							
JP 07505408	W	19950615	(199532)			A61K009-107	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9320800	A1	WO 1993-FI149	19930407
AU 9338925	A	AU 1993-38925	19930407
EP 634926	A1	EP 1993-907890	19930407
		WO 1993-FI149	19930407
JP 07505408	W	JP 1993-518017	19930407
		WO 1993-FI149	19930407

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9338925	A Based on	WO 9320800
EP 634926	A1 Based on	WO 9320800
JP 07505408	W Based on	WO 9320800

PRIORITY APPLN. INFO: US 1992-865256 19920408

REFERENCE PATENTS: WO 8607540

INT. PATENT CLASSIF.:

MAIN: A61K009-107; A61K009-127

SECONDARY: A61K047-48; A61K049-04

BASIC ABSTRACT:

WO 9320800 A UPAB: 19931213

A compsn. for therapeutic or diagnostic use comprises a carrier and a lysosmotropic agent. The carrier consists of lipoproteins, other types of microemulsion particles, liposomes and micelles containing a lipo- or amphi-philic active agent, associated with at least one ligand which is complementary to and recognisable by a specific cell receptor.

The carrier is pref. reconstituted Low Density Lipoprotein (LDL) and the lysosmotropic agent is pref. Triton WR 1339 ethyl oleate. The therapeutic or diagnostic agent is pref. a light sensitiser (e.g. hematoporphyrin), radiosensitiser (e.g. boronated fatty acid esters), X-ray contrast agent or anti-cancer drug (e.g. doxorubicin, daunomycin or 1-hexadecyl-2-methyl-3-phosphocholine).

Pref. compsn. contains the anti-cancer drug chlorambucil cholesteryl ester. Pref. compsn. comprises a reconstituted LDL containing chlorambucil cholesteryl ester and Triton WR 1339 ethyl oleate.

USE - The compsn. is useful for therapeutic and diagnostic treatment of humans and animals. The cell-specific ligand targets the active agent to the site of interest, such as cancerous tissue and therefore concentrates the action at the site. The compsn. is pref. used parenterally.

Dwg.0/2

FILE SEGMENT: CPI
FIELD AVAILABILITY: AB; DCN
MANUAL CODES: CPI: B01-D02; C01-D02; B02-D; C02-D; B04-B01B; C04-B01B;
B04-C03D; C04-C03D; **B05-B01A**;
C05-B01A; B05-B01P; C05-B01P; B06-D18;
C06-D18; **B12-M03**; **C12-M03**;
B12-M11F; C12-M11F

=> FIL STNGUIDE

=>

=> fil zcaplus

FILE 'ZCAPLUS' ENTERED AT 12:40:49 ON 27 MAY 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS is strictly prohibited.

FILE COVERS 1907 - 27 May 2004 VOL 140 ISS 22
FILE LAST UPDATED: 26 May 2004 (20040526/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 12:40:52 ON 27 MAY 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 May 2004 VOL 140 ISS 22
FILE LAST UPDATED: 26 May 2004 (20040526/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> fil biosis

FILE 'BIOSIS' ENTERED AT 12:40:55 ON 27 MAY 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC. (R)

FILE COVERS 1969 TO DATE.
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 26 May 2004 (20040526/ED)

FILE RELOADED: 19 October 2003.

=> fil uspatfull

FILE 'USPATFULL' ENTERED AT 12:41:00 ON 27 MAY 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 27 May 2004 (20040527/PD)
FILE LAST UPDATED: 27 May 2004 (20040527/ED)
HIGHEST GRANTED PATENT NUMBER: US6742188
HIGHEST APPLICATION PUBLICATION NUMBER: US2004103464
CA INDEXING IS CURRENT THROUGH 27 May 2004 (20040527/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 27 May 2004 (20040527/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2004
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2004

```
>>> USPAT2 is now available. USPATFULL contains full text of the    <<<
>>> original, i.e., the earliest published granted patents or      <<<
>>> applications. USPAT2 contains full text of the latest US       <<<
>>> publications, starting in 2001, for the inventions covered in   <<<
>>> USPATFULL. A USPATFULL record contains not only the original   <<<
>>> published document but also a list of any subsequent           <<<
>>> publications. The publication number, patent kind code, and    <<<
>>> publication date for all the US publications for an invention  <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc.                                                       <<<
```

```
>>> USPATFULL and USPAT2 can be accessed and searched together     <<<
>>> through the new cluster USPATALL. Type FILE USPATALL to        <<<
>>> enter this cluster.                                             <<<
>>>                                                                    <<<
>>> Use USPATALL when searching terms such as patent assignees,    <<<
>>> classifications, or claims, that may potentially change from   <<<
>>> the earliest to the latest publication.                         <<<
```

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> FIL STNGUIDE

FILE 'STNGUIDE' ENTERED AT 12:41:03 ON 27 MAY 2004
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 21, 2004 (20040521/UP).

=> d que l119

```
L1 (      120)SEA FILE=REGISTRY ABB=ON  PLU=ON  B>=1 AND (4432.3.5)/RID
L2 (          5)SEA FILE=HCAPLUS ABB=ON  PLU=ON  328563-79-7?
L3 (          2)SEA FILE=HCAPLUS ABB=ON  PLU=ON  L2 AND BCH
L4 (          1)SEA FILE=HCAPLUS ABB=ON  PLU=ON  427880-16-8?
L5 (          1)SEA FILE=HCAPLUS ABB=ON  PLU=ON  427880-18-0?
L6 (        59)SEA FILE=HCAPLUS ABB=ON  PLU=ON  L1
L7 (        59)SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L1 OR L2 OR L3 OR L4 OR L5
      OR L6)
L8 (          1)SEA FILE=REGISTRY ABB=ON  PLU=ON  TRIOLEIN/CN
```

L9 111711 SEA FILE=HCAPLUS ABB=ON PLU=ON (?GLYCERID? OR ?MONOGLYCERID?
 OR ?DIGLYCERID? OR ?TRIGLYCERID? OR ?TRIOLEIN?)/CW
 L10 14129 SEA FILE=HCAPLUS ABB=ON PLU=ON MONOGLYCERIDES+PFT,NT,RT/CT
 L11 13112 SEA FILE=HCAPLUS ABB=ON PLU=ON DIGLYCERIDES+PFT,NT,RT/CT
 L12 127444 SEA FILE=HCAPLUS ABB=ON PLU=ON GLYCERIDES+PFT,NT,RT/CT
 L13 3757 SEA FILE=HCAPLUS ABB=ON PLU=ON L8
 L14 1 SEA FILE=HCAPLUS ABB=ON PLU=ON L7 AND (L9 OR L10 OR L11 OR
 L12 OR L13)
 L15 1 SEA FILE=HCAPLUS ABB=ON PLU=ON (?GLYCER? OR ?TRIOLEIN?) AND
 L7
 L16 1 SEA FILE=REGISTRY ABB=ON PLU=ON LYSOZYME/CN
 L18 43 SEA FILE=REGISTRY ABB=ON PLU=ON AVIDIN/CNS
 L19 2 SEA FILE=REGISTRY ABB=ON PLU=ON POLYLYSINE/CN
 L20 24723 SEA FILE=HCAPLUS ABB=ON PLU=ON L16 OR L18 OR L19
 L21 4016 SEA FILE=HCAPLUS ABB=ON PLU=ON (?LYSOZYM? OR ?AVIDIN? OR
 ?POLYLYS?)/CW
 L22 46237 SEA FILE=HCAPLUS ABB=ON PLU=ON ?LYSOZYM? OR ?AVIDIN? OR
 ?POLYLYS?
 L23 28338 SEA FILE=HCAPLUS ABB=ON PLU=ON LYSOZYME/CT OR AVIDINS/CT OR
 (POLYLYSINE/CT OR POLY-L-LYSINE/CT OR "POLY-L-LYSINE, SRU"/CT)
 L24 1 SEA FILE=HCAPLUS ABB=ON PLU=ON (L20 OR L21 OR L22 OR L23)
 AND L7
 L25 67910 SEA FILE=HCAPLUS ABB=ON PLU=ON (?LIPOPROTEIN? OR ?CHYLOMICRON
 ?)/CW
 L26 92431 SEA FILE=HCAPLUS ABB=ON PLU=ON LIPOPROTEINS+PFT,NT,RT/CT
 L27 42248 SEA FILE=HCAPLUS ABB=ON PLU=ON CHYLOMICRONS/CT OR CHYLOMICRON
 /CT OR "FATS AND GLYCERIDIC OILS"/CT
 L28 4 SEA FILE=HCAPLUS ABB=ON PLU=ON (L25 OR L26 OR L27) AND L7
 L29 3 SEA FILE=HCAPLUS ABB=ON PLU=ON (LDL? OR ?VLDL? OR IDL? OR
 HDL? OR ?CHYLOMICRON?) AND L7
 L30 (120)SEA FILE=REGISTRY ABB=ON PLU=ON B>=1 AND (4432.3.5)/RID
 L31 (5)SEA FILE=HCAPLUS ABB=ON PLU=ON 328563-79-7?
 L32 (2)SEA FILE=HCAPLUS ABB=ON PLU=ON L31 AND BCH
 L33 (1)SEA FILE=HCAPLUS ABB=ON PLU=ON 427880-16-8?
 L34 (1)SEA FILE=HCAPLUS ABB=ON PLU=ON 427880-18-0?
 L35 (59)SEA FILE=HCAPLUS ABB=ON PLU=ON L30
 L36 (59)SEA FILE=HCAPLUS ABB=ON PLU=ON L32 OR (L33 OR L34 OR L35)
 L37 (97751)SEA FILE=HCAPLUS ABB=ON PLU=ON (?SPHINGOMYELIN? OR ?CEPHALIN?
 OR ?PHOSPHATIDYL? OR ?PHOSPHATIDIC? OR ?ISOLECTIN? OR
 ?PHOSPHOLIPID?)/CW
 L38 (3)SEA FILE=HCAPLUS ABB=ON PLU=ON L36 AND L37
 L39 (73)SEA FILE=HCAPLUS ABB=ON PLU=ON 57-88-5? (L) (?BORO? OR
 ?BORAN? OR ?BORAX? OR ?BORAH? OR ?BORIC?)
 L40 (474)SEA FILE=HCAPLUS ABB=ON PLU=ON 57-88-5? (L) (?EMULSION?)
 L41 (2)SEA FILE=HCAPLUS ABB=ON PLU=ON L40 AND (?BORO? OR ?BORAN? OR
 ?BORAX? OR ?BORAH? OR ?BORIC?)
 L42 (75)SEA FILE=HCAPLUS ABB=ON PLU=ON L39 OR L41
 L43 (11)SEA FILE=HCAPLUS ABB=ON PLU=ON L42 AND L37
 L44 13 SEA FILE=HCAPLUS ABB=ON PLU=ON L38 OR L43
 L45 (120)SEA FILE=REGISTRY ABB=ON PLU=ON B>=1 AND (4432.3.5)/RID
 L46 (5)SEA FILE=HCAPLUS ABB=ON PLU=ON 328563-79-7?
 L47 (2)SEA FILE=HCAPLUS ABB=ON PLU=ON L46 AND BCH
 L48 (1)SEA FILE=HCAPLUS ABB=ON PLU=ON 427880-16-8?
 L49 (1)SEA FILE=HCAPLUS ABB=ON PLU=ON 427880-18-0?
 L50 (59)SEA FILE=HCAPLUS ABB=ON PLU=ON L45
 L51 (97751)SEA FILE=HCAPLUS ABB=ON PLU=ON (?SPHINGOMYELIN? OR ?CEPHALIN?
 OR ?PHOSPHATIDYL? OR ?PHOSPHATIDIC? OR ?ISOLECTIN? OR
 ?PHOSPHOLIPID?)/CW
 L52 (73)SEA FILE=HCAPLUS ABB=ON PLU=ON 57-88-5? (L) (?BORO? OR
 ?BORAN? OR ?BORAX? OR ?BORAH? OR ?BORIC?)

L53 (474) SEA FILE=HCAPLUS ABB=ON PLU=ON 57-88-5? (L) (?EMULSION?)
 L54 (2) SEA FILE=HCAPLUS ABB=ON PLU=ON L53 AND (?BORO? OR ?BORAN? OR
 ?BORAX? OR ?BORAH? OR ?BORIC?)
 L55 (75) SEA FILE=HCAPLUS ABB=ON PLU=ON L52 OR L54
 L56 (168532) SEA FILE=HCAPLUS ABB=ON PLU=ON (PHOSPHOLIPIDS/CT OR "ALPHA
 LIPID 300"/CT OR ASOLECTINS/CT OR AZOLECTINS/CT OR DARMSTOFF/CT
 OR "EMULPUR N"/CT OR "EPIKURON 110"/CT OR "EPUKURON 170"/CT
 OR "LIPOID E 80"/CT OR "NAT 3003"/CT OR "NAT 89"/CT OR
 "OVOTHIN 120"/CT OR "OVOTHIN 170"/CT OR PHOSPHODERM/CT OR
 PHOSPHOLIPINS/CT OR PLATELIN/CT OR GLYCEROPHOSPHOLIPIDS/CT OR
 CEPHALINS/CT OR DIPHOSPHOINOSITIDES/CT OR LECITHIN/CT OR
 LYSOPHOSPHOLIPIDS/CT OR LYSOPHOSPHATIDALETHANOLAMINES/CT OR
 LYSOPHOSPHATIDALINOSITOLS/CT OR LYSOPHOSPHATIDES/CT OR
 LYSOCARDIOLIPINS/CT OR LYSOCEPHALINS/CT OR LYSOCYTHINS/CT OR
 LYSOLECITHIN/CT OR LYSOLECITHINS/CT OR LYSOPHOSPHATIDALCHOLINES
 /CT OR LYSOPHOSPHATIDALINOSITOLS/CT OR LYSOPHOSPHATIDALSERINES/
 CT OR LYSOPHOSPHATIDALTHREONINES/CT OR "LYSOPHOSPHATIDIC
 ACID"/CT OR "LYSOPHOSPHATIDIC ACIDS"/CT OR LYSOPHOSPHATIDYLCHOL
 INES/CT OR LYSOPHOSPHATIDYLETHANOLAMINE/CT OR LYSOPHOSPHATIDYLE
 THANOLAMINES/CT OR LYSOPHOSPHATIDYLGLYCEROLS/CT OR LYSOPHOSPHAT
 IDYLINOSITOLS/CT OR LYSOPHOSPHATIDYL SERINES/CT OR LYSOPHOSPHATI
 DYLTHREONINES/CT OR LYSOPHOSPHOINOSITIDES/CT OR LYSOPLASMALOGEN
 S/CT OR "PHOSPHATIDES (L) ALKALOIDAL, PYRROLOPHENANTHRIDINE"/CT
 OR "PHOSPHATIDES (L) PHOSPHATIDYLBUTANOLS"/CT OR "PHOSPHATIDES
 (L) PHOSPHATIDYLETHANOLS"/CT OR "PHOSPHATIDIC ACIDS"/CT OR
 "DIPALMITOYLPHOSPHATIDIC ACID"/CT OR "LYSOPHOSPHATIDIC
 ACID"/CT OR "LYSOPHOSPHATIDIC ACIDS"/CT OR "PLASMALOGENIC
 ACIDS"/CT OR PHOSPHATIDYLCHOLINES/CT OR 1-PALMITOYL-2-OLEOYL-L-
 A-PHOSPHATIDYLCHOLINE/CT OR 1-PALMITOYL-2-OLEOYLPHOSPHATI
 DYLCHOLINE/CT OR DILAULOYLPHOSPHATIDYLCHOLINE/CT OR DIMYRISTOYL
 PHOSPHATIDYLCHOLINE/CT OR DIOLEOYLPHOSPHATIDYLCHOLINE/CT OR
 DIPALMITOYLPHOSPHATIDYLCHOLINE/CT OR DISTEAROYLPHOSPHATIDYLCHOL
 INE/CT OR GLYCEROPHOSPHOCHOLINE/CT OR GLYCOLLECITHINS/CT OR
 L-DIMYRISTOYLPHOSPHATIDYLCHOLINE/CT OR L-DIOLEOYLPHOSPHATIDYLCH
 OLINE/CT OR L-DIPALMITOYLPHOSPHATIDYLCHOLINE/CT OR L-DISTEAROYL
 PHOSPHATIDYLCHOLINE/CT OR LYSOCYTHINS/CT OR LYSOLECITHIN/CT OR
 LYSOLECITHINS/CT OR LYSOPHOSPHATIDYLCHOLINES/CT OR "PLATEL
 L57 (59) SEA FILE=HCAPLUS ABB=ON PLU=ON (L45 OR L46 OR L47 OR L48 OR
 L49 OR L50)
 L58 33 SEA FILE=HCAPLUS ABB=ON PLU=ON (L57 OR L55) AND (L51 OR L56)
 L59 35 SEA FILE=HCAPLUS ABB=ON PLU=ON L14 OR L15 OR L24 OR L28 OR
 L29 OR L44 OR L58
 L60 9 SEA FILE=HCAPLUS ABB=ON PLU=ON L7 AND ?LIPID?
 L61 17 SEA FILE=HCAPLUS ABB=ON PLU=ON L7 AND (?LIPID? OR ?LIPO?)
 L62 43 SEA FILE=HCAPLUS ABB=ON PLU=ON (L59 OR L60 OR L61)
 L65 30 SEA FILE=HCAPLUS ABB=ON PLU=ON L62 AND (PRY<2002 OR PY<2002
 OR AY<2002)
 L73 2449541 SEA FILE=HCAPLUS ABB=ON PLU=ON (?COLLOID? OR ?EMULS? OR
 ?LAYER? OR ?CORE? OR ?AMPHIPHATH? OR ?HYDROPHOB? OR ?HYDROPHIL?
 OR ?LAMELL? OR ?MICELL?)
 L74 18 SEA FILE=HCAPLUS ABB=ON PLU=ON L65 AND L73
 L75 15 SEA FILE=HCAPLUS ABB=ON PLU=ON L74 NOT ((FOOD OR FEED
 CHEMISTRY)/SC OR (FOSSIL FUELS)/SC OR (CARBOHYDRATES)/SC)
 L76 351453 SEA FILE=HCAPLUS ABB=ON PLU=ON (DRUG DELIVER? OR RADIOTHER?
 OR IMAG? OR PHARMACEUT? OR DIAGNOS?)/CW
 L77 17 SEA FILE=HCAPLUS ABB=ON PLU=ON L76 AND L65
 L78 6 SEA FILE=HCAPLUS ABB=ON PLU=ON L77 NOT L74
 L79 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L78 NOT ((BIOCHEMICAL
 GENETICS)/SC OR SAIMIRI/IT)

L80 6 SEA FILE=HCAPLUS ABB=ON PLU=ON L65 NOT (L74 OR L78)
 L81 1 SEA FILE=HCAPLUS ABB=ON PLU=ON L80 AND CARBOHYDRATES/SC
 L82 20 SEA FILE=HCAPLUS ABB=ON PLU=ON L79 OR L75 OR L81
 L119 16 SEA FILE=HCAPLUS ABB=ON PLU=ON L82 NOT (MONOSACCHARIDE OR
 SPIN LABELS OR REDUCING SUGARS OR CORNEUM)/TI

=> d que l120

L83 168 SEA FILE=BIOSIS ABB=ON PLU=ON ?CHOLEST? (L) (?BORO? OR
 ?BORIC? OR ?BORAN? OR ?BORAX?)
 L84 633075 SEA FILE=BIOSIS ABB=ON PLU=ON (?COLLOID? OR ?EMULS? OR
 ?LAYER? OR ?CORE? OR ?AMPHIPATH? OR ?HYDROPHOB? OR ?HYDROPHIL?
 OR ?LAMEL? OR ?MICELL?)
 L86 28 SEA FILE=BIOSIS ABB=ON PLU=ON L84 AND L83
 L87 10 SEA FILE=BIOSIS ABB=ON PLU=ON L86 AND (TETRAPHENYLBORON OR
 BORON NEUTRON-CAPTURE OR BORON NEUTRON CAPTURE OR MURINE
 TUMORS OR XENOGRAFTS OR BNCT OR VLDL OR CHOLESTERYL CARBORANE)/
 TI
 L88 31 SEA FILE=BIOSIS ABB=ON PLU=ON L83 AND (?DRUG? OR ?RADIOTHER?
 OR ?IMAG? OR ?PHARMACEUT?)
 L89 25 SEA FILE=BIOSIS ABB=ON PLU=ON L88 NOT L86
 L90 6 SEA FILE=BIOSIS ABB=ON PLU=ON L89 AND (BRATTLEBORO OR DRUG
 DELIVERY OR BORON NEUTRON CAPTURE)/TI
 L91 5 SEA FILE=BIOSIS ABB=ON PLU=ON L90 NOT CORTICAL/TI
 L93 15 SEA FILE=BIOSIS ABB=ON PLU=ON L87 OR L91
 L120 13 SEA FILE=BIOSIS ABB=ON PLU=ON L93 NOT (BRATTLEBORO OR
 TETRAPHENYLBORON)/TI

=> d que l114

L68 120 SEA FILE=REGISTRY ABB=ON PLU=ON B>=1 AND (4432.3.5)/RID
 L70 4 SEA FILE=REGISTRY ABB=ON PLU=ON L68 AND USPATFULL/LC
 L72 4 SEA FILE=USPATFULL ABB=ON PLU=ON L70
 L101 2 SEA FILE=USPATFULL ABB=ON PLU=ON L72 AND (A61K049-00 OR
 C07J009-00)/ICM
 L114 2 SEA FILE=USPATFULL ABB=ON PLU=ON L101 AND (?EMULS? OR
 ?LAYER? OR ?LAMELL? OR ?MICELL? OR ?AMPHIPATH? OR ?COLLOID? OR
 ?HYDROPHOB? OR ?HYDROPHIL?)/BI

=> dup rem l119 l120 l114

FILE 'HCAPLUS' ENTERED AT 12:41:44 ON 27 MAY 2004
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 12:41:44 ON 27 MAY 2004
 COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'USPATFULL' ENTERED AT 12:41:44 ON 27 MAY 2004
 CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
 PROCESSING COMPLETED FOR L119
 PROCESSING COMPLETED FOR L120
 PROCESSING COMPLETED FOR L114

L131 26 DUP REM L119 L120 L114 (5 DUPLICATES REMOVED)
 ANSWERS '1-16' FROM FILE HCAPLUS
 ANSWERS '17-25' FROM FILE BIOSIS
 ANSWER '26' FROM FILE USPATFULL

=> FIL STNGUIDE

FILE 'STNGUIDE' ENTERED AT 12:42:52 ON 27 MAY 2004
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: May 21, 2004 (20040521/UP).

=> d l131 iall hitstr

YOU HAVE REQUESTED DATA FROM FILE 'USPATFULL, HCAPLUS, BIOSIS' - CONTINUE? (Y)/N:y

L131 ANSWER 1 OF 26 HCAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 1999:602799 HCAPLUS

DOCUMENT NUMBER: 131:337242

ENTRY DATE: Entered STN: 23 Sep 1999

TITLE: Synthesis of boron-containing cholesterol derivatives
for incorporation into **unilamellar**
liposomes and evaluation as potential agents
for BNCT

AUTHOR(S): Feakes, Debra A.; Spinler, Jennifer K.; Harris, Fred
R.

CORPORATE SOURCE: Chemistry Department, Southwest Texas State
University, San Marcos, TX, 78666, USA

SOURCE: Tetrahedron (1999), 55(37), 11177-11186
CODEN: TETRAB; ISSN: 0040-4020

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

CLASSIFICATION: 32-7 (Steroids)

Section cross-reference(s): 29

ABSTRACT:

Four carborane-containing derivs. of cholesterol were prepared for incorporation into the **bilayer** of **unilamellar liposomes** and evaluation as potential agents for boron neutron capture therapy. The derivs. enable the evaluation of the linker moiety and the type of carborane head group on the **bilayer** stability and ultimate in vivo tumor specificity.

SUPPL. TERM: cholesterol boron contg deriv prepn; BNCT boron contg
cholesterol

INDEX TERM: Radiotherapy
(boron-neutron capture; synthesis of boron-containing
cholesterol derivs. for incorporation into
unilamellar liposomes and evaluation as
potential agents for BNCT)

INDEX TERM: Carboranes
ROLE: RCT (Reactant); SPN (Synthetic preparation); PREP
(Preparation); RACT (Reactant or reagent)
(synthesis of boron-containing cholesterol derivs.)

INDEX TERM: 57-88-5, Cholesterol, reactions 17702-41-9, Decaborane
20739-58-6, 2-Octyn-1-ol

INDEX TERM: ROLE: RCT (Reactant); RACT (Reactant or reagent)
(synthesis of boron-containing cholesterol derivs.)

INDEX TERM: 871-91-0P, 7-Octyn-1-ol 13860-68-9P 245436-38-8P
249903-49-9P 249903-50-2P 249903-52-4P
249903-53-5P, 1,2-Dicarbododecaborane(12)-1-hexanol

249903-54-6P

ROLE: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of boron-containing cholesterol derivs.)

INDEX TERM:

250220-21-4P 250220-23-6P

ROLE: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of boron-containing cholesterol derivs.)

REFERENCE COUNT:

21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD.

REFERENCE(S):

- (1) Clendonon, N; Neurosurgery 1990, V26, P47
- (2) Coderre, J; Cancer Res 1988, V48, P6313 HCAPLUS
- (3) Deamer, D; Liposomes 1983, P31
- (4) Fairchild, R; J Radiat Oncol Biol Phys 1985, V11, P831 HCAPLUS
- (5) Feakes, D; Proc Natl Acad Sci USA 1994, V91, P3029 HCAPLUS
- (6) Feakes, D; Proc Natl Acad Sci USA 1995, V92, P1367 HCAPLUS
- (7) Fraley, R; Biochemistry 1981, V20, P6978 HCAPLUS
- (8) Gabel, D; Cancer Res 1987, V47, P5451 HCAPLUS
- (9) Hawthorne, M; Inorg Synth 1967, V9, P16 HCAPLUS
- (10) Hawthorne, M; Inorg Synth 1967, V10, P91 HCAPLUS
- (11) Macaulay, S; J Org Chem 1980, V45, P734 HCAPLUS
- (12) Proffitt, R; J Nucl Med 1983, V24, P45 HCAPLUS
- (13) Shelly, K; Proc Natl Acad Sci USA 1992, V89, P9039 HCAPLUS
- (14) Slatkin, D; Biochem Pharmacol 1986, V35, P1771 HCAPLUS
- (15) Soloway, A; Medicinal Chem 1967, V10, P714 HCAPLUS
- (16) Srivastava, R; J Org Chem 1997, V62, P8730 HCAPLUS
- (17) Straubinger, R; Biochemistry 1990, V29, P4929 HCAPLUS
- (18) Straubinger, R; Cell 1983, V32, P1069 HCAPLUS
- (19) Sweet, W; Pharmacol Exp Ther 1962, V137, P263 HCAPLUS
- (20) Tomita, H; Inorg Chem 1991, V30, P812 HCAPLUS
- (21) Wallingford, R; J Nucl Med 1985, V26, P1180 HCAPLUS

IT

249903-49-9P 249903-50-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of boron-containing cholesterol derivs.)


RN

249903-49-9 HCAPLUS

CN

Cholest-5-en-3-ol (3 β)-, 6-(1,2-dicarbadoecaboran(12)-1-yl)hexanoate
(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—CHMe₂

RN 249903-50-2 HCAPLUS
 CN 1,2-Dicarbadodecaborane(12), 1-[6-[(3β)-cholest-5-en-3-yloxy]hexyl]-
 (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—CHMe₂

IT 250220-21-4P 250220-23-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of boron-containing cholesterol derivs.)

RN 250220-21-4 HCAPLUS

CN 1-Butanaminium, N,N,N-tributyl-, 7-[6-[(3β)-cholest-5-en-3-yloxy]-6-oxohexyl]undecahydro-7,8-dicarbaundecaborate(1-) (9CI) (CA INDEX NAME)

CM 1

CRN 250220-20-3

CMF C35 H66 B9 O2


CCI CCS

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

CM 2

CRN 10549-76-5
CMF C16 H36 N




RN 250220-23-6 HCAPLUS
CN 1-Butanaminium, N,N,N-tributyl-, 7-[6-[(3 β)-cholest-5-en-3-yloxy]hexyl]undecahydro-7,8-dicarbaundecaborate(1-) (9CI) (CA INDEX NAME)


CM 1

CRN 250220-22-5
CMF C35 H68 B9 O
CCI CCS

PAGE 1-A




PAGE 1-B



CM 2

CRN 10549-76-5

CMF C16 H36 N



=> d l131 iall hitstr 2-16

YOU HAVE REQUESTED DATA FROM FILE 'USPATFULL, HCAPLUS, BIOSIS' - CONTINUE? (Y)/N:y

L131 ANSWER 2 OF 26 HCAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 3

ACCESSION NUMBER: 1998:173232 HCAPLUS

DOCUMENT NUMBER: 128:267754

ENTRY DATE: Entered STN: 25 Mar 1998

TITLE: Model studies directed toward the application of boron neutron capture therapy to rheumatoid arthritis: boron delivery by liposomes in rat collagen-induced arthritis

AUTHOR(S): Watson-Clark, Rachel A.; Banquerigo, Mona Lisa; Shelly, Kenneth; Hawthorne, M. Frederick; Brahn, Ernest

CORPORATE SOURCE: Department of Chemistry and Biochemistry, University of California, Los Angeles, CA, 90095, USA

SOURCE: Proceedings of the National Academy of Sciences of the United States of America (1998), 95(5), 2531-2534

CODEN: PNASA6; ISSN: 0027-8424

PUBLISHER: National Academy of Sciences

DOCUMENT TYPE: Journal

LANGUAGE: English
 CLASSIFICATION: 8-9 (Radiation Biochemistry)
 Section cross-reference(s): 63

ABSTRACT:

The application of boron neutron capture therapy to rheumatoid arthritis requires the selective delivery of the boron-10 isotope to the synovitis tissue. The use of liposomes as a boron delivery method has been explored through the measurement of the time course biodistribution of boron in rats with collagen-induced arthritis (CIA). Small **unilamellar** vesicles were composed of a 1:1 mixture of distearoylphosphatidylcholine and cholesterol, incorporated K[nido-7-CH₃(CH₂)₁₅-7,8-C₂B₉H₁₁] as an addend in the lipid *****bilayer***** and encapsulated Na₃[α -B₂O₃H₁₇NH₂CH₂CH₂NH₂] in the aqueous *****core*****. The tissue concentration of boron delivered by liposomes was determined by inductively coupled plasma-atomic emission spectroscopy after i.v. injection of liposome suspensions into Louvain rats with CIA. With the low injected doses of boron used [13-18 mg of boron per kg (body weight)], the peak boron concentration observed in arthritic synovium was 29 μ g of boron per g of tissue. The highest synovium/blood boron ratio observed was 3.0, when the synovial boron concentration was 22 μ g of boron per g of tissue. In an attempt to increase the synovium/blood boron ratio by lowering the blood boron concentration, a liposomal formulation characterized by a shorter blood clearance time was examined. Thus, the biodistribution of liposomes with addnl. K[nido-7-CH₃(CH₂)₁₅-7,8-C₂B₉H₁₁] incorporated in the vesicle membrane not only demonstrated more rapid blood clearance and slightly higher synovium/blood boron ratios but also exhibited reduced boron uptake in synovial tissue. These studies with boron neutron capture therapy for CIA suggest that this form of therapy may be feasible in the treatment of rheumatoid arthritis.

SUPPL. TERM: boron neutron capture therapy rheumatoid arthritis;
 liposomal boron delivery synovial tissue

INDEX TERM: Radiotherapy
 (boron-neutron capture; model studies directed toward application of boron neutron capture therapy to rheumatoid arthritis: boron delivery by liposomes in collagen-induced arthritis)

INDEX TERM: Drug delivery systems
 (liposomes; model studies directed toward application of boron neutron capture therapy to rheumatoid arthritis: boron delivery by liposomes in collagen-induced arthritis)

INDEX TERM: Rheumatoid arthritis
 Synovial membrane
 (model studies directed toward application of boron neutron capture therapy to rheumatoid arthritis: boron delivery by liposomes in collagen-induced arthritis)

INDEX TERM: 165290-42-6 180907-06-6
 ROLE: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (model studies directed toward application of boron neutron capture therapy to rheumatoid arthritis: boron delivery by liposomes in collagen-induced arthritis)

INDEX TERM: 57-88-5, Cholesterol, uses 4539-70-2,
 Distearoylphosphatidylcholine
 ROLE: MOA (Modifier or additive use); USES (Uses)
 (model studies directed toward application of boron neutron capture therapy to rheumatoid arthritis: boron delivery by liposomes in

collagen-induced arthritis)

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD.

- REFERENCE(S):
- (1) Binello, E; Advances in Neutron Capture Therapy 1997, VI, P459
 - (2) Fairchild, R; J Radiat Oncol Biol Phys 1985, V11, P831 HCAPLUS
 - (3) Feakes, D; Proc Natl Acad Sci USA 1994, V91, P3029 HCAPLUS
 - (4) Feakes, D; Proc Natl Acad Sci USA 1995, V92, P1367 HCAPLUS
 - (5) Georgiev, E; Inorg Chem 1996, V35, P5412 HCAPLUS
 - (6) Harling, O; Nucl Sci Eng 1992, V110, P330 HCAPLUS
 - (7) Harris, E; Rheumatoid Arthritis 1997, Pxix
 - (8) Hwang, K; Liposomes: From Biophysics to Therapeutics 1987, P109
 - (9) Johnson, D; Anal Chim Acta 1992, V270, P223 HCAPLUS
 - (10) Johnson, L; Cancer Neutron Capture Therapy 1996, P183 HCAPLUS
 - (11) Kelley, W; Textbook of Rheumatology 1989, P1934
 - (12) Locher, G; Am J Roentogenol Radium Ther 1936, V36, P1 HCAPLUS
 - (13) Peacock, D; Cell Immun 1995, V160, P178 HCAPLUS
 - (14) Peacock, D; J Exp Med 1992, V175, P1135 HCAPLUS
 - (15) Shelly, K; Proc Natl Acad Sci USA 1992, V89, P9039 HCAPLUS
 - (16) Straubinger, R; Biochemistry 1990, V29, P4929 HCAPLUS

IT 57-88-5, Cholesterol, uses 4539-70-2,
Distearoylphosphatidylcholine


RL: MOA (Modifier or additive use); USES (Uses)

(model studies directed toward application of **boron** neutron capture therapy to rheumatoid arthritis: **boron** delivery by liposomes in collagen-induced arthritis)

RN 57-88-5 HCAPLUS


CN Cholest-5-en-3-ol (3 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 4539-70-2 HCAPLUS

CN 3,5,9-Trioxa-4-phosphaheptacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxooctadecyl)oxy]-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



L131 ANSWER 3 OF 26 HCAPLUS, COPYRIGHT 2004 ACS on STN DUPLICATE 4

ACCESSION NUMBER: 1998:399473 HCAPLUS

DOCUMENT NUMBER: 129:99958

ENTRY DATE: Entered STN: 01 Jul 1998

TITLE: Liposomes containing boronophenylalanine for boron neutron capture therapy

AUTHOR(S): Perugini, P.; Pavanetto, F.

CORPORATE SOURCE: Dep. of Pharmaceutical Chem., Univ. of Pavia, Pavia, 27100, Italy

SOURCE: Journal of Microencapsulation (1998), 15(4), 473-483

CODEN: JOMIEF; ISSN: 0265-2048

PUBLISHER: Taylor & Francis Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

CLASSIFICATION: 63-6 (Pharmaceuticals)

Section cross-reference(s): 8

ABSTRACT:

In the present work, liposomes loaded with boronophenylalanine (BPA), with or without stabilization, were formulated for the application in boron neutron capture therapy. BPA was encapsulated into liposomes as a complex with fructose, but also as a free drug in 2 different pH buffers. The influence of critical variables (cholesterol content, drug:lipid molar ratio, osmotic stress of liposomes containing hyperosmotic drug solution) on liposome morphol. and drug content

was evaluated. The drug content and dissoln. profile of different BPA loaded liposomes were also studied. The phys. stability of liposomes in terms of changes in the size distribution in different osmotic pressure buffers and the chemical oxidation of phospholipids during storing conditions were investigated. The

encapsulation efficiencies of all formulations were always satisfactory, being between 20-48%; even when the liposomes were exposed to high osmotic stress, the particle size was below 200 nm. The BPA-fructose complex loaded liposomes showed a slower drug release profile.

SUPPL. TERM: liposomes boronophenylalanine boron neutron capture therapy

INDEX TERM: Radiotherapy

(boron-neutron capture; liposomes containing boronophenylalanine for boron neutron capture therapy)

INDEX TERM: **Lecithins**

ROLE: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(egg yolk; liposomes containing boronophenylalanine for boron neutron capture therapy)

INDEX TERM: Dissolution rate

Encapsulation

Particle size distribution

(liposomes containing boronophenylalanine for boron neutron capture therapy)

INDEX TERM: Drug delivery systems
(liposomes, **unilamellar**; liposomes containing boronophenylalanine for boron neutron capture therapy)

INDEX TERM: **Gangliosides**
ROLE: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monosialogangliosides; liposomes containing boronophenylalanine for boron neutron capture therapy)

INDEX TERM: 57-48-7, Fructose, biological studies **57-88-5**, Cholesterol, biological studies 90580-64-6, DL-p-Boronophenylalanine
ROLE: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liposomes containing **boronophenylalanine** for **boron** neutron capture therapy)

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD.


REFERENCE(S): (1) Barth, R; Cancer 1992, V70, P2995 MEDLINE
(2) Gabizon, A; Proceedings of the National Academy of Science USA 1988, V85, P6949 HCAPLUS
(3) Hawthorne, M; Angewandte Chemie International Edition in English 1993, V32, P950
(4) Mallesch, J; International Journal of Radiation Oncology, Biology and Physics 1994, V28, P1183 MEDLINE
(5) Metha, S; Journal of Microencapsulation 1996, V13, P269
(6) Metha, S; Pharmaceutical Research 1996, V13, P344
(7) Mishima, Y; Lancet 1989, VII, P388
(8) Mori, Y; Pigment Cell Research 1989, V2, P273 HCAPLUS
(9) New, R; Liposomes: a practical approach 1990, P105
(10) Pidgeon, C; Analytical Biochemistry 1989, V181, P28 HCAPLUS
(11) Pinelli, T; Proceedings of 6th International Symposium on NCT for cancer 1994, P783
(12) Shelly, K; Proceedings of the National Academy of Science, USA 1992, V89, P9039 HCAPLUS
(13) Szoka, F; Biochimica and Biophysics Acta 1980, V601, P559 HCAPLUS
(14) Uchiyama, K; International Journal of Pharmaceutics 1995, V121, P195 HCAPLUS

IT **57-88-5**, Cholesterol, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liposomes containing **boronophenylalanine** for **boron** neutron capture therapy)

RN 57-88-5 HCAPLUS

CN Cholest-5-en-3-ol (3 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L131 ANSWER 4 OF 26 HCAPLUS: COPYRIGHT 2004 ACS on STN DUPLICATE 5

ACCESSION NUMBER: 1994:528879 HCAPLUS

DOCUMENT NUMBER: 121:128879

ENTRY DATE: Entered STN: 17 Sep 1994

TITLE: Na3[B20H17NH3]: Synthesis and liposomal delivery to murine tumors

AUTHOR(S): Feakes, Debra A.; Shelly, Kenneth; Knobler, Carolyn B.; Hawthorne, M. Frederick

CORPORATE SOURCE: Dep. Chem. Biochem., Univ. California, Los Angeles, CA, 90024, USA

SOURCE: Proceedings of the National Academy of Sciences of the United States of America (1994), 91(8), 3029-33

CODEN: PNASA6; ISSN: 0027-8424

DOCUMENT TYPE: Journal

LANGUAGE: English

CLASSIFICATION: 8-9 (Radiation Biochemistry)

Section cross-reference(s): 14

ABSTRACT:

The polyhedral borane ion [n-B20H18]2- reacts with liquid ammonia in the presence of a suitable base to produce an apical-equatorial (ae) isomer of the [B20H17NH3]3- ion, [1-(2'-B10H9)-2-NH3B10H8]3-. The structure of this product has been confirmed by 11B NMR spectroscopy and x-ray crystallog. This species undergoes acid-catalyzed rearrangement to an apical-apical (a2) isomer, [1-(1'-B10H9)-2-NH3B10H8]3-, whose structure has been determined by 11B NMR spectroscopy. The sodium salts of both the ae and the a2 isomers of [B20H17NH3]3- have been encapsulated within small **unilamellar** liposomes, composed of distearoylphosphatidylcholine/cholesterol (1:1), and investigated as boron-delivery agents for boron neutron capture therapy (BNCT) of cancer. The biodistribution of boron was determined after the injection of liposomal suspensions into BALB/c mice bearing EMT6 tumors. Both [B20H17NH3]3- isomers exhibited excellent tumor uptake and selectivity at very low injected doses, achieving peak tumor boron concns. of 30-40 µg of B/g of tissue and tumor/blood boron ratios of ≈5. The enhanced retention of the [B20H17NH3]3- isomers by EMT6 tumors may be attributed to their facile intracellular oxidation to an extremely reactive NH3-substituted [n-B20H18]2- ion, the electrophilic [B20H17NH3]- ion. Both isomers of [B20H17NH3]3- are at least 0.5 V more easily oxidized than other previously investigated species containing 20 boron atoms. In another experiment, [ae-B20H17NH3]3- was encapsulated in liposomes prepared with 5% PEG-2000-distearoylphosphatidylethanolamine in the liposome membrane. As expected, these liposomes exhibited a longer circulation lifetime in the biodistribution experiment, resulting in the continued accumulation of boron in the tumor over the entire 48-h experiment and reaching a maximum of 47 µg of B/g of tumor.

SUPPL. TERM: liposomal polyhedral borane prepn delivery tumor; boron
neutron capture radiotherapy liposomal borane

INDEX TERM: Neoplasm
(liposomal polyhedral borane delivery to, boron-neutron
capture radiotherapy in relation to)

INDEX TERM: Pharmaceutical dosage forms
(liposomes, polyhedral borane-containing, preparation and
tumor
delivery of, boron-neutron capture radiotherapy in
relation to)


INDEX TERM: **4539-70-2P**, Distearoyl phosphatidylcholine
157143-39-0P 157143-41-4P
ROLE: SPN (Synthetic preparation); PREP (Preparation)
(liposomal, preparation and tumor delivery of, boron-neutron
capture radiotherapy in relation to)

INDEX TERM: **57-88-5P**, Cholesterol, biological studies
4537-76-2P, Distearoylphosphatidylethanolamine
ROLE: SPN (Synthetic preparation); PREP (Preparation)
(liposome, polyhedral **borane**-containing, preparation and
tumor delivery of, **boron**-neutron capture
radiotherapy in relation to)

IT **4539-70-2P**, Distearoyl phosphatidylcholine
RL: SPN (Synthetic preparation); PREP (Preparation)
(liposomal, preparation and tumor delivery of, boron-neutron capture
radiotherapy in relation to)

RN 4539-70-2 HCAPLUS

CN 3,5,9-Trioxa-4-phosphaheptacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-
oxo-7-[(1-oxooctadecyl)oxy]-, inner salt, 4-oxide (9CI) (CA INDEX NAME)




IT **57-88-5P**, Cholesterol, biological studies
RL: SPN (Synthetic preparation); PREP (Preparation)
(liposome, polyhedral **borane**-containing, preparation and tumor
delivery of, **boron**-neutron capture radiotherapy in relation
to)

RN 57-88-5 HCAPLUS

CN Cholest-5-en-3-ol (3 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L131 ANSWER 5 OF 26 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:593220 HCAPLUS

DOCUMENT NUMBER: 135:170765

ENTRY DATE: Entered STN: 16 Aug 2001

TITLE: Compositions for boron delivery to mammalian tissue

INVENTOR(S): Hawthorne, M. Frederick; Feaks, Debra Arlene; Shelly, Kenneth John

PATENT ASSIGNEE(S): Reagents of the University of California, USA

SOURCE: U.S., 29 pp., Cont.-in-part of U.S. 5,888,473.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

INT. PATENT CLASSIF.: A61K051-00; A61K091-27

US PATENT CLASSIF.: 424012100

CLASSIFICATION: 63-5 (Pharmaceuticals)

Section cross-reference(s): 8, 29

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6274116	B1	20010814	US 1999-280098	19990329 <--
US 5648532	A	19970715	US 1993-71702	19930603 <--
US 5888473	A	19990330	US 1995-511073	19950803 <--
US 6517808	B1	20030211	US 2001-837147	20010418 <--

PRIORITY APPLN. INFO.:

US 1993-71702	A3	19930603 <--
US 1995-511073	A2	19950803 <--
US 1999-280098	A3	19990329 <--

OTHER SOURCE(S): MARPAT 135:170765

ABSTRACT:

Boron neutron capture therapy can utilize $XyB_{20}H_{17}L$ where X is an alkali metal, y is 1 to 4, and L is a two electron donor such as NH_3 , and $Na_2B_{10}H_9NCO$, among others. These borane salts may be used free or encapsulated in liposomes. Liposomes may also have embedded within their **bilayers** carboranes to increase the amount of delivered ^{10}B and/or to increase the tumor specificity of the liposome.

SUPPL. TERM: liposome boron compd prepn tumor BNCT

INDEX TERM: NMR (nuclear magnetic resonance)
(boron-11; liposomal compns. for boron delivery to tumors)

INDEX TERM: Radiotherapy
(boron-neutron capture; liposomal compns. for boron delivery to tumors)

INDEX TERM: Antitumor agents

Crystal structure

Neoplasm

(liposomal compns. for boron delivery to tumors)

INDEX TERM:

Phospholipids, uses

ROLE: MOA (Modifier or additive use); USES (Uses)

(liposomal compns. for boron delivery to tumors)

INDEX TERM:

Proteins, general, biological studies

ROLE: BPR (Biological process); BSU (Biological study,

unclassified); BIOL (Biological study); PROC (Process)

(liposomal compns. for boron delivery to tumors: reaction
with intracellular proteins)

INDEX TERM:

Drug delivery systems

(liposomes; liposomal compns. for boron delivery to
tumors)

INDEX TERM:

7440-42-8, Boron, biological studies

ROLE: BPR (Biological process); BSU (Biological study,

unclassified); BIOL (Biological study); PROC (Process)

(liposomal compns. for boron delivery to tumors)

INDEX TERM:

12294-20-1 144885-51-8 157143-38-9 165178-93-8

165290-42-6 176105-69-4 180907-07-7 213134-11-3

ROLE: BPR (Biological process); BSU (Biological study,

unclassified); THU (Therapeutic use); BIOL (Biological

study); PROC (Process); USES (Uses)

(liposomal compns. for boron delivery to tumors)

INDEX TERM:

57-88-5, Cholesterol, uses 816-94-4, DSPC

ROLE: MOA (Modifier or additive use); USES (Uses)

(liposomal compns. for boron delivery to
tumors)

INDEX TERM:

354134-69-3

ROLE: PRP (Properties)

(liposomal compns. for boron delivery to tumors)

INDEX TERM:

112-89-0 629-89-0, 1-Octadecyne 12075-73-9 12356-22-8

12404-15-8 17702-35-1 17702-41-9, Decaborane(14)

55914-86-8 165178-78-9 165306-81-0

ROLE: RCT (Reactant); RACT (Reactant or reagent)

(liposomal compns. for boron delivery to tumors)

INDEX TERM:

165178-77-8P

ROLE: RCT (Reactant); SPN (Synthetic preparation); PREP

(Preparation); RACT (Reactant or reagent)

(liposomal compns. for boron delivery to tumors)

INDEX TERM:

141664-81-5P 141684-17-5P 141684-19-7P 164072-14-4P

165178-80-3P 165178-82-5P 165178-83-6P 165178-89-2P

165178-90-5P 165178-92-7P 165306-80-9P 165337-85-9P

354134-72-8P

ROLE: SPN (Synthetic preparation); PREP (Preparation)

(liposomal compns. for boron delivery to tumors)

REFERENCE COUNT:

5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD.

REFERENCE(S):

(1) Anon; WO 9222298 1992 HCAPLUS

(2) Fujii; US 5328678 1994 HCAPLUS

(3) Kane; US 5856551 1999 HCAPLUS

(4) Shelly, K; Proc Natl Acad Sci 1992, V89, P9039 HCAPLUS

(5) Spielvogel; US 5272250 1993 HCAPLUS

IT **57-88-5, Cholesterol, uses 816-94-4, DSPC**


RL: MOA (Modifier or additive use); USES (Uses)

(liposomal compns. for boron delivery to tumors)

RN 57-88-5 HCAPLUS

CN Cholest-5-en-3-ol (3 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 816-94-4 HCAPLUS

CN 3,5,9-Trioxa-4-phosphaheptacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxooctadecyl)oxy]-, inner salt, 4-oxide, (7R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L131 ANSWER 6 OF 26 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:310719 HCAPLUS

DOCUMENT NUMBER: 138:44571

ENTRY DATE: Entered STN: 25 Apr 2002

TITLE: SLT-particles for two-step targeting in boron neutron capture therapy

AUTHOR(S): Bohl, E.; Carlsson, J.; Edwards, K.; Sjoberg, S.; Gedda, L.

CORPORATE SOURCE: Biomedical Radiation Sciences Rudbeck Laboratory, Uppsala, 75185, Swed.

SOURCE: Frontiers in Neutron Capture Therapy, [Proceedings of the International Symposium on Neutron Capture Therapy for Cancer], 8th, Los Angeles, CA, United States, Sept. 13-18, 1998 (2001), Meeting Date 1998, Volume 2, 1069-1075. Editor(s): Hawthorne, M. Frederick; Shelly, Kenneth; Wiersema, Richard J. Kluwer Academic/Plenum Publishers: New York, N. Y. CODEN: 69CMQV; ISBN: 0-306-46442-X

DOCUMENT TYPE: Conference

LANGUAGE: English

CLASSIFICATION: 63-5 (Pharmaceuticals)

Section cross-reference(s): 8

ABSTRACT:

The magnitude of the unspecific cellular uptake of liposome encapsulated boronated DNA intercalators was determined. It is essential that the unspecific drug delivery is at a low level to ensure low damage to healthy tissue. The boronated DNA-intercalating agents water-soluble boronated acridine WSA-1 and

water soluble boronated phenanthridine WSP-1 were used in the study. Uptake ***monolayer*** U-343 glioma cells of WSA-1, WSA-1 in stabilized liposomes, WSP-1, and WSP-1 in stabilized liposomes was studied. The binding in DU-145 prostatic spheroids was studied using WSA-1, WSA-1 in stabilized liposomes, WSP-1 and WSP-1 in stabilized liposomes in a concentration of 5µg/mL. The clonogenic survival test showed that after 24 h incubation the liposome encapsulated compds. did exhibit a less toxic behavior than the free compds. The most toxic compound WSP-1 showed a large decrease in survival even at low concns. Since the stabilized liposomes loaded with boronated DNA-intercalating compds. are to be used in two-step targeting the unspecific uptake should be low. It is also very significant that the liposomes are able to penetrate into spheroids since they are to be used in hunting tumors.


SUPPL. TERM: boronated DNA intercalator liposome tumor uptake
 INDEX TERM: Intercalation
 (agents; tumor cell uptake of liposome-encapsulated DNA-intercalating boron compds.)
 INDEX TERM: Radiotherapy
 (boron-neutron capture; liposome particles for two-step targeting in boron neutron capture therapy)
 INDEX TERM: Neoplasm
 Neuroglia, neoplasm
 (glioma cell uptake of liposome-encapsulated boron compds.)
 INDEX TERM: Drug delivery systems
 (liposomes; liposome particles for two-step targeting in boron neutron capture therapy)
 INDEX TERM: Human
 (tumor cell uptake of liposome-encapsulated DNA-intercalating boron compds.)
 INDEX TERM: DNA
 ROLE: BSU (Biological study, unclassified); BIOL (Biological study)
 (tumor cell uptake of liposome-encapsulated DNA-intercalating boron compds.)
 INDEX TERM: 200135-21-3, WSP-1 206347-16-2, WSA-1
 ROLE: ADV (Adverse effect, including toxicity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (liposome particles for two-step targeting in boron neutron capture therapy)
 INDEX TERM: 57-88-5, Cholesterol, biological studies
 4539-70-2, DSPC 145035-96-7, DSPE-PEG
 ROLE: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (liposome particles for two-step targeting in boron neutron capture therapy)
 REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD.
 REFERENCE(S): (1) Allen, T; Biochimia et Biophysica Acta 1995, V1237, P99 HCAPLUS
 (2) Feakes, D; Proc Natl Acad Sci USA 1995, V92, P1367 HCAPLUS
 (3) Gedda, L; Comprehensive Summaries of Dissertations from the Faculty of Medicine 1997, V724
 (4) Ghaneolhosseini, H; Comprehensive summaries of Uppsala Dissertations from the Faculty of Science and Technology 1998, V356
 (5) Hartman, T; Radiotherapy and Oncology 1993, V31, P61
 (6) Hawthorne, M; Oncology 1997, V33, P53 MEDLINE

- (7) Lindstrom, P; Anti-Cancer Drugs 1994, V5, P43 MEDLINE
 (8) Nemoto, H; J Med Chem 1995, V38, P1673 HCAPLUS
 (9) Shelly, K; Proc Natl Acad Sci USA 1992, V89, P9039 HCAPLUS
 (10) Woodle, M; Advanced Drug Delivery Reviews V16, P249 HCAPLUS


IT 57-88-5, Cholesterol, biological studies 4539-70-2, DSPC
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (liposome particles for two-step targeting in boron neutron capture therapy)

RN 57-88-5 HCAPLUS
 CN Cholest-5-en-3-ol (3 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 4539-70-2 HCAPLUS
 CN 3,5,9-Trioxa-4-phosphaheptacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxooctadecyl)oxy]-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



L131 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:347002 HCAPLUS

DOCUMENT NUMBER: 138:95452

ENTRY DATE: Entered STN: 09 May 2002

TITLE: Tumor cell-selective delivery of boron compounds via folate receptor-targeted liposomes

AUTHOR(S): Pan, X.; Shukla, S.; Sekido, M.; Tjarks, W.; Adams, D.; Barth, R.; Ji, W.; Wang, H.; Shi, G.; Sudimack, J.; Guo, W.; Lee, R. L.

CORPORATE SOURCE: College of Pharmacy, The Ohio State University, Columbus, OH, 43210, USA

SOURCE: Proceedings - 28th International Symposium on Controlled Release of Bioactive Materials and 4th Consumer & Diversified Products Conference, San Diego, CA, United States, June 23-27, 2001 (2001),

Volume 1, 580-581. Controlled Release Society:
Minneapolis, Minn.
CODEN: 69CNY8
Conference
English
63-6 (Pharmaceuticals)
Section cross-reference(s): 8

DOCUMENT TYPE:
LANGUAGE:
CLASSIFICATION:

ABSTRACT:

Encapsulation efficiency of boron-derivatized polyamine compds. (SPD-5, ASPD-5, ASPM-5, SPM-5,10, and BBSPD-5) in liposomes with four different methods are evaluated. Tumor uptake of boron-containing liposomes in culture KB cells were also studied. The efficiency of boron encapsulation in liposomes is highly dependent on the trapping agent. The use of (NH₄)₂SO₄ as a trapping agent was more effective than usage of citric acid. Folate-PEG-liposomes showed excellent target cell specificity and warrant further evaluation as a carrier for tumor-selective delivery of boron for boron neutron capture therapy (BNCT).

SUPPL. TERM: boron polyamine folate PEG liposome tumor targeting
INDEX TERM: **Radiotherapy**
(boron-neutron capture; encapsulation efficiency of boron-derivatized compds. in liposomes and tumor uptake of boron-containing liposomes for boron neutron capture therapy)

INDEX TERM: **Phosphatidylethanolamines, biological studies**
ROLE: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugates with PEG and folic acid; encapsulation efficiency of boron-derivatized compds. in liposomes and tumor uptake of boron-containing liposomes for boron neutron capture therapy)

INDEX TERM: Polyoxyalkylenes, biological studies
ROLE: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugates with folic acid and PE; encapsulation efficiency of boron-derivatized compds. in liposomes and tumor uptake of boron-containing liposomes for boron neutron capture therapy)

INDEX TERM: **Drug delivery systems**
Encapsulation
Human
Particle size distribution
Radiotherapy
(encapsulation efficiency of boron-derivatized compds. in liposomes and tumor uptake of boron-containing liposomes for boron neutron capture therapy)

INDEX TERM: **Phosphatidylcholines, biological studies**
ROLE: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(encapsulation efficiency of boron-derivatized compds. in liposomes and tumor uptake of boron-containing liposomes for boron neutron capture therapy)

INDEX TERM: **Drug delivery systems**
(liposomes; encapsulation efficiency of boron-derivatized compds. in liposomes and tumor uptake of boron-containing liposomes for boron neutron capture therapy)

INDEX TERM: Amines, biological studies
ROLE: BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); PROC (Process); USES (Uses)
 (polyamines, nonpolymeric; encapsulation efficiency of
 boron-derivatized compds. in liposomes and tumor uptake
 of boron-containing liposomes for boron neutron capture
 therapy)

INDEX TERM: Biological transport
 (uptake; encapsulation efficiency of boron-derivatized
 compds. in liposomes and tumor uptake of boron-containing
 liposomes for boron neutron capture therapy)

INDEX TERM: 12294-22-3 164072-14-4
 ROLE: BSU (Biological study, unclassified); PEP (Physical,
 engineering or chemical process); PYP (Physical process);
 BIOL (Biological study); PROC (Process)
 (encapsulation efficiency of boron-derivatized compds. in
 liposomes)

INDEX TERM: 165823-32-5P 186037-03-6P 226881-22-7P 226881-23-8P
 226881-26-1P
 ROLE: BSU (Biological study, unclassified); PEP (Physical,
 engineering or chemical process); PRP (Properties); PYP
 (Physical process); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); PROC (Process); USES (Uses)
 (encapsulation efficiency of boron-derivatized compds. in
 liposomes and tumor uptake of boron-containing liposomes for
 boron neutron capture therapy)

INDEX TERM: 57-88-5, Cholesterol, biological studies 59-30-3,
 Folic acid, biological studies 59-30-3D, Folic acid,
 conjugates with PEG and PE 25322-68-3D, PEG, conjugates
 with folic acid and PE 27321-96-6
 ROLE: THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)
 (encapsulation efficiency of boron-derivatized
 compds. in liposomes and tumor uptake of boron
 -containing liposomes for boron neutron capture
 therapy)

INDEX TERM: 77-92-9, Citric acid, biological studies 7783-20-2,
 Ammonium sulfate ((NH₄)₂SO₄), biological studies
 ROLE: BUU (Biological use, unclassified); THU (Therapeutic
 use); BIOL (Biological study); USES (Uses)
 (trapping agent; encapsulation efficiency of
 boron-derivatized compds. in liposomes and tumor uptake
 of boron-containing liposomes for boron neutron capture
 therapy)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
 RECORD.


REFERENCE(S): (1) Johnsson; J Liposome Res 1999, V9, P53 HCAPLUS
 (2) Lee; Biol Chem 1994, V269, P3198 HCAPLUS
 (3) Soloway; Chem Rev 1998, V98, P1515 HCAPLUS

IT 57-88-5, Cholesterol, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (encapsulation efficiency of boron-derivatized compds. in
 liposomes and tumor uptake of boron-containing liposomes for
 boron neutron capture therapy)

RN 57-88-5 HCAPLUS

CN Cholest-5-en-3-ol (3 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L131 ANSWER 8 OF 26 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:18290 HCAPLUS

DOCUMENT NUMBER: 135:247084

ENTRY DATE: Entered STN: 09 Jan 2001

TITLE: Preparation and evaluation of **unilamellar liposomes** incorporating boron-containing derivatives of cholesterol

AUTHOR(S): Feakes, Debora A.; Tate, Colby C.; Stefanutti, Sara J.

CORPORATE SOURCE: Department of Chemistry and Biochemistry, Southwest Texas State University, San Marcos, TX, 78666, USA

SOURCE: KURRI-KR (2000), KURRI-KR-54, 155-156

CODEN: KURRBF; ISSN: 1342-0852

DOCUMENT TYPE: Report

LANGUAGE: English

CLASSIFICATION: 63-5 (Pharmaceuticals)

ABSTRACT:

The application of boron neutron capture therapy is dependent on the identification and preparation of boron-containing compds. that can be delivered and retained by the tumor cells. **Unilamellar liposomes** have been investigated as potential tumor-specific delivery vehicles for boron-containing compds. that have no inherent tumor specificity. A series of carborane-containing derivs. of cholesterol have been prepared and incorporated into the **bilayer** of **unilamellar liposomes**. The cholesterol derivs. vary in the linker moiety (ester and ether), the chain length between the cholesterol and the carborane substituent, and the identity of the carborane group itself (closo- and nido-). The ability of the boron-containing derivs. of cholesterol to be incorporated into the **bilayer** of the **unilamellar liposomes** and the stability of the resulting **liposome** formulations will be presented.

SUPPL. TERM: cholesterol carborane contg deriv **liposome** BNCT

INDEX TERM: Radiotherapy
(boron-neutron capture; preparation and evaluation of **unilamellar liposomes** incorporating boron-containing derivs. of cholesterol)

INDEX TERM: Drug delivery systems
(**liposomes**; preparation and evaluation of **unilamellar liposomes** incorporating boron-containing derivs. of cholesterol)

INDEX TERM: Drug targeting
(preparation and evaluation of **unilamellar liposomes** incorporating boron-containing derivs. of cholesterol)

INDEX TERM: Carboranes
ROLE: RCT (Reactant); RACT (Reactant or reagent)

(preparation and evaluation of **unilamellar liposomes** incorporating boron-containing derivs. of cholesterol)

INDEX TERM: 249903-49-9P 359851-17-5P

ROLE: SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and evaluation of **unilamellar liposomes** incorporating boron-containing derivs. of cholesterol)

INDEX TERM: 816-94-4, DSPC

ROLE: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation and evaluation of **unilamellar liposomes** incorporating boron-containing derivs. of cholesterol)

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD.

REFERENCE(S): (1) Clendonon, N; Neurosurgery 1990, V26, P47
(2) Coderre, J; Cancer Res 1988, V48, P6313 HCAPLUS
(3) Deamer, D; Liposomes 1983, P31
(4) Feakes, D; Proc Natl Acad Sci USA 1994, V91, P3029 HCAPLUS
(5) Feakes, D; Proc Natl Acad Sci USA 1995, V92, P1367 HCAPLUS
(6) Feakes, D; Proc Natl Acad Sci USA 1999, V96, P6406 HCAPLUS
(7) Feakes, D; Tetrahedron 1999, V55, P11177 HCAPLUS
(8) Fraley, R; Biochemistry 1981, V20, P6978 HCAPLUS
(9) Gabel, D; Cancer Res 1987, V47, P5451 HCAPLUS
(10) Proffitt, R; J Nucl Med 1983, V24, P45 HCAPLUS
(11) Shelly, K; Proc Natl Acad Sci USA 1992, V89, P9039 HCAPLUS
(12) Slatkin, D; Biochem Pharmacol 1986, V35, P1771 HCAPLUS
(13) Soloway, A; Medicinal Chem 1967, V10, P714 HCAPLUS
(14) Straubinger, R; Biochemistry 1990, V29, P4929 HCAPLUS
(15) Straubinger, R; Cell 1983, V32, P1069 HCAPLUS
(16) Sweet, W; J Pharmacol Exp Ther 1962, V137, P263 HCAPLUS
(17) Tamat, S; Anal Chem 1987, V59, P2161 HCAPLUS
(18) Wallingford, R; J Nucl Med 1985, V26, P1180 HCAPLUS

IT 249903-49-9P 359851-17-5P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and evaluation of **unilamellar liposomes** incorporating boron-containing derivs. of cholesterol)

RN 249903-49-9 HCAPLUS

CN Cholest-5-en-3-ol (3 β)-, 6-(1,2-dicarbadodecaboran(12)-1-yl)hexanoate (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—CHMe₂

RN 359851-17-5 HCAPLUS
 CN Cholest-5-en-3-ol (3β)-, 9-(1,2-dicarbado-dodecaboran(12)-1-yl)nonanoate
 (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—CHMe₂


IT 816-94-4, DSPC

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (preparation and evaluation of **unilamellar liposomes**
 incorporating boron-containing derivs. of cholesterol)

RN 816-94-4 HCAPLUS

CN 3,5,9-Trioxa-4-phosphaheptacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-
 oxo-7-[(1-oxooctadecyl)oxy]-, inner salt, 4-oxide, (7R) - (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.



L131 ANSWER 9 OF 26 HCAPLUS COPYRIGHT 2004 ACS on STN

3/4

Mohamed 09/916,028

05/27/2004

ACCESSION NUMBER: 1999:404815 HCAPLUS
 DOCUMENT NUMBER: 131:56154
 ENTRY DATE: Entered STN: 01 Jul 1999
 TITLE: Optoacoustic contrast agents and methods for their use
 in ultrasound and optical imaging
 INVENTOR(S): Unger, Evan C.; Wu, Yunqiu
 PATENT ASSIGNEE(S): ImaRx Pharmaceutical Corp., USA
 SOURCE: PCT Int. Appl., 166 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 INT. PATENT CLASSIF.:
 MAIN: A61B008-13
 SECONDARY: A61K049-00
 CLASSIFICATION: 9-16 (Biochemical Methods)
 Section cross-reference(s): 8, 63
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9930620	A1	19990624	WO 1998-US27060	19981217 <--
W: AU, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6123923	A	20000926	US 1997-993165	19971218 <--
AU 9919318	A1	19990705	AU 1999-19318	19981217 <--
EP 1039834	A1	20001004	EP 1998-964127	19981217 <--
R: DE, FR, GB, IT				
PRIORITY APPLN. INFO.:			US 1997-993165 A	19971218 <--
			WO 1998-US27060 W	19981217 <--

ABSTRACT:

The present invention generally relates to optoacoustic contrast agents and methods of diagnostic and therapeutic imaging using optoacoustic contrast agents. A composition comprising a stabilizing material and a photoactive agent is administered and the patient is scanned using ultrasound imaging and optical imaging to obtain visible images of a region of the patient. The compns. may comprise a wide variety of addnl. components, including, for example, one or more of gases, gaseous precursors, liqs. oils, stabilizing materials, diagnostic agents, photoactive agents, bioactive agents, and/or targeting ligands. Perfluoropropane encapsulated optoacoustic **liposomes** were formed from dipalmitoylphosphatidylcholine, dipalmitoylphosphatidic acid, dipalmitoylphosphatidylethanolamine-PEG 5,000, and dipalmitoylphosphatidylethanolamine derivatized with lissamine rhodamine B. The sized photoactive **lipid** was optimally excited with 550 nm light and the fluorescence emission peak was 590 nm.

SUPPL. TERM: optoacoustic contrast agent optical ultrasound imaging;
liposome perfluoropropane lissamine rhodamine B
 optoacoustic contrast agent
 INDEX TERM: **Imaging**
 (acoustic; optoacoustic contrast agents and methods for
 their use in ultrasound and optical imaging)
 INDEX TERM: Nucleic acids
 Oligodeoxyribonucleotides
 ROLE: ARG (Analytical reagent use); BPR (Biological
 process); BSU (Biological study, unclassified); THU
 (Therapeutic use); ANST (Analytical study); BIOL (Biological
 study); PROC (Process); USES (Uses)
 (antigene, as targeting ligand, composition further
 containing;

optoacoustic contrast agents and methods for their use in
ultrasound and optical imaging)

INDEX TERM: Cyanine dyes
Fluorescent substances
Photosensitizers (**pharmaceutical**)
(as photoactive agent; optoacoustic contrast agents and
methods for their use in ultrasound and optical imaging)

INDEX TERM: Bile pigments
Biliproteins
Carotenes, biological studies
Flavonoids
Fullerenes
Metalloporphyrins
Phycocyanins
Phycoerythrins
Phytochromes
Porphyrins
ROLE: ARG (Analytical reagent use); THU (Therapeutic use);
ANST (Analytical study); BIOL (Biological study); USES
(Uses)
(as photoactive agent; optoacoustic contrast agents and
methods for their use in ultrasound and optical imaging)

INDEX TERM: Proteins, general, biological studies
ROLE: ARG (Analytical reagent use); BPR (Biological
process); BSU (Biological study, unclassified); THU
(Therapeutic use); ANST (Analytical study); BIOL (Biological
study); PROC (Process); USES (Uses)
(as stabilizer or targeting ligand; optoacoustic contrast
agents and methods for their use in ultrasound and
optical imaging)

INDEX TERM: Surfactants
(as stabilizer; optoacoustic contrast agents and methods
for their use in ultrasound and optical imaging)

INDEX TERM: **Lipids**, biological studies
Polymers, biological studies
ROLE: ARG (Analytical reagent use); THU (Therapeutic use);
ANST (Analytical study); BIOL (Biological study); USES
(Uses)
(as stabilizer; optoacoustic contrast agents and methods
for their use in ultrasound and optical imaging)

INDEX TERM: Antibodies
Antisense DNA
Antisense RNA
Antisense oligonucleotides
Carbohydrates, biological studies
DNA
Gene, animal
Glycolipids
Lipoproteins
Oligonucleotides
Peptides, biological studies
RNA
Ribozymes
ROLE: ARG (Analytical reagent use); BPR (Biological
process); BSU (Biological study, unclassified); THU
(Therapeutic use); ANST (Analytical study); BIOL (Biological
study); PROC (Process); USES (Uses)
(as targeting ligand, composition further containing;
optoacoustic
contrast agents and methods for their use in ultrasound

and optical imaging)
INDEX TERM: Porphyrins
ROLE: ARG (Analytical reagent use); THU (Therapeutic use);
ANST (Analytical study); BIOL (Biological study); USES
(Uses)
(benzoporphyrins, as photoactive agent; optoacoustic
contrast agents and methods for their use in ultrasound
and optical imaging)
INDEX TERM: Porphyrins
ROLE: ARG (Analytical reagent use); THU (Therapeutic use);
ANST (Analytical study); BIOL (Biological study); USES
(Uses)
(chlorins, as photoactive agent; optoacoustic contrast
agents and methods for their use in ultrasound and
optical imaging)
INDEX TERM: Gases
(composition further containing gaseous precursor and or;
optoacoustic contrast agents and methods for their use in
ultrasound and optical imaging)
INDEX TERM: Drugs
(composition further containing; optoacoustic contrast agents
and
methods for their use in ultrasound and optical imaging)
INDEX TERM: Perfluorocarbons
ROLE: ARG (Analytical reagent use); THU (Therapeutic use);
ANST (Analytical study); BIOL (Biological study); USES
(Uses)
(composition further containing; optoacoustic contrast agents
and
methods for their use in ultrasound and optical imaging)
INDEX TERM: Polyenes
ROLE: ARG (Analytical reagent use); THU (Therapeutic use);
ANST (Analytical study); BIOL (Biological study); USES
(Uses)
(conjugated, as photoactive agent; optoacoustic contrast
agents and methods for their use in ultrasound and
optical imaging)
INDEX TERM: Antibodies
ROLE: ARG (Analytical reagent use); THU (Therapeutic use);
ANST (Analytical study); BIOL (Biological study); USES
(Uses)
(conjugates, with photoactive agent; optoacoustic
contrast agents and methods for their use in ultrasound
and optical imaging)
INDEX TERM: Unsaturated compounds
ROLE: ARG (Analytical reagent use); THU (Therapeutic use);
ANST (Analytical study); BIOL (Biological study); USES
(Uses)
(cyanines, as photoactive agent; optoacoustic contrast
agents and methods for their use in ultrasound and
optical imaging)
INDEX TERM: Disease, animal
(diagnosis of; optoacoustic contrast agents and methods
for their use in ultrasound and optical imaging)
INDEX TERM: **Phosphatidylethanolamines, biological studies**
ROLE: ARG (Analytical reagent use); THU (Therapeutic use);
ANST (Analytical study); BIOL (Biological study); USES
(Uses)
(fluorescein conjugates, perfluorobutane encapsulated in
optoacoustic **liposomes** containing; optoacoustic

contrast agents and methods for their use in ultrasound and optical imaging)

INDEX TERM: Liquids
(fluorinated, composition further containing; optoacoustic contrast agents and methods for their use in ultrasound and optical imaging)

INDEX TERM: Surfactants
(fluorosurfactants, as stabilizer; optoacoustic contrast agents and methods for their use in ultrasound and optical imaging)

INDEX TERM: RNA
Ribozymes
ROLE: ARG (Analytical reagent use); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PROC (Process); USES (Uses)
(hammerhead, as targeting ligand, composition further containing; optoacoustic contrast agents and methods for their use in ultrasound and optical imaging)

INDEX TERM: **Diagnosis**
(of diseased tissue; optoacoustic contrast agents and methods for their use in ultrasound and optical imaging)

INDEX TERM: Liquids
(oils, composition further containing; optoacoustic contrast agents and methods for their use in ultrasound and optical imaging)

INDEX TERM: **Imaging**
Neoplasm
Sound and Ultrasound
Stabilizing agents
(optoacoustic contrast agents and methods for their use in ultrasound and optical imaging)

INDEX TERM: **Imaging agents**
(optoacoustic contrast agents; optoacoustic contrast agents and methods for their use in ultrasound and optical imaging)

INDEX TERM: Thrombus
(optoacoustic **liposomes** targeting; optoacoustic contrast agents and methods for their use in ultrasound and optical imaging)

INDEX TERM: Perfluoro compounds
Perfluoro compounds
ROLE: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(perfluoroalkyl ethers, composition further containing; optoacoustic contrast agents and methods for their use in ultrasound and optical imaging)

INDEX TERM: Ethers, biological studies
Ethers, biological studies
ROLE: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(perfluoroalkyl, composition further containing; optoacoustic contrast agents and methods for their use in ultrasound and optical imaging)

INDEX TERM: Materials
(photoactive chems.; optoacoustic contrast agents and methods for their use in ultrasound and optical imaging)

INDEX TERM: Solids
(porous matrix; optoacoustic contrast agents and methods for their use in ultrasound and optical imaging)

INDEX TERM: Interleukin 2
ROLE: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of targeting optoacoustic contrast agent for thrombus; optoacoustic contrast agents and methods for their use in ultrasound and optical imaging)

INDEX TERM: Thrombolytics
(targeting optoacoustic **liposomes** for; optoacoustic contrast agents and methods for their use in ultrasound and optical imaging)

INDEX TERM: Ligands
ROLE: ARG (Analytical reagent use); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PROC (Process); USES (Uses)
(targeting, composition further containing; optoacoustic contrast agents and methods for their use in ultrasound and optical imaging)

INDEX TERM: 106-60-5, 8-Aminolevulinic acid 302-79-4, Retinoic acid 302-79-4D, Retinoic acid, derivs. 479-61-8 553-12-8, Protoporphyrin IX 574-93-6D, Phthalocyanine, derivs. 603-34-9D, Triphenylamine, derivs. 643-79-8, o-Phthaldialdehyde 917-23-7D, Tetraphenylporphine, sulfonated derivs. 1075-06-5, Phenylglyoxal monohydrate 1210-12-4, 9-Anthronitrile 2321-07-5D, Fluorescein, derivs. 3599-32-4, Indocyanine green 5143-18-0 7149-49-7, Naphthalene-2,3-dicarboxaldehyde 12713-07-4D, Verdin, derivs. 12778-00-6, Mesochlorin 13558-31-1D, derivs. 14325-05-4, Tin protoporphyrin 14459-29-1, Hematoporphyrin 19660-77-6, Chlorin e6 19660-77-6D, Chlorin e6, mono-L-aspartyl derivative 23627-89-6D, Naphthalocyanine, derivs. 25440-13-5 26038-83-5, 4-Heptadecyl-7-hydroxycoumarin 41085-99-8 41387-42-2 60415-70-5D, 21H,23H-Porphin-5(22H)-one, derivs. 61494-52-8, 1-Pyrenesulfonyl chloride 62796-29-6, Lissamine rhodamine B sulfonyl chloride 62888-19-1, Bonellin 65603-18-1 65603-19-2, Octadecyl rhodamine B chloride 68335-15-9, Photofrin 72467-67-5 72535-39-8 73024-99-4, 12-(9-Anthroyloxy)oleic acid 75168-11-5 76081-97-5, Cholesteryl 1-pyrenebutyrate 78949-95-8 88235-25-0 88478-07-3 95864-17-8 96886-70-3 97850-83-4, Cholesteryl 1-pyrenedecanoate 99128-91-3, Octaethylpurpurin 100572-96-1D, Porphycene, compds. 105344-74-9 113471-15-1 114041-00-8 114494-17-6 114586-25-3 115645-42-6 123738-53-4 123940-54-5, Hypocrellin B 128146-77-0 134020-79-4D, Sapphyrin, derivs. 135615-37-1D, Rubyrin, derivs. 138026-68-3 147662-88-2, 2-Dodecylresorufin **151736-99-1** 151892-94-3 186833-02-3 216434-81-0 217187-10-5 227936-56-3D, 2,4,1,2,5-Oxatellurazole, derivs. 227936-57-4
ROLE: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(as photoactive agent; optoacoustic contrast agents and methods for their use in ultrasound and optical imaging)

INDEX TERM: 75-73-0 76-16-4 76-19-7, Perfluoropropane 115-25-3, Perfluorocyclobutane 306-94-5, Perfluorodecalin 307-34-6, Perfluorooctane 307-45-9, Perfluorodecane 307-59-5, Perfluorododecane 311-89-7, Perfluorotributylamine 335-57-9, Perfluoroheptane 338-83-0, Perfluorotripropylamine 355-25-9, Perfluorobutane 355-42-0, Perfluorohexane 355-68-0, Perfluorocyclohexane 355-79-3, Perfluorotetrahydropyran 356-62-7, Bis(perfluoropropyl) ether 358-21-4, Perfluorodiethyl ether 375-03-1, Perfluoropropylmethyl ether 375-96-2, Perfluorononane 376-77-2, Perfluorocyclopentane 423-55-2, Perfluorooctylbromide 507-63-1, Perfluorooctyliodide 665-16-7, Perfluoromethylethyl ether 678-26-2, Perfluoropentane 931-91-9, Perfluorocyclopropane 1479-49-8, Perfluorodimethyl ether 2551-62-4, Sulfur hexafluoride 13782-76-8, Perfluorobutylethyl ether 19448-33-0 51001-25-3D, perfluoro 66840-50-4 83935-39-1, Bis(perfluoroisopropyl) ether 163702-07-6, Perfluorobutylmethyl ether 199171-52-3 199171-53-4
 ROLE: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (composition further containing; optoacoustic contrast agents and
 and
 methods for their use in ultrasound and optical imaging)
 INDEX TERM: 10199-89-0
 ROLE: ARG (Analytical reagent use); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PROC (Process); USES (Uses)
 (conjugates with diacylphosphatidyl ethanolamine, thrombus targeting optoacoustic **liposomes** containing; optoacoustic contrast agents and methods for their use in ultrasound and optical imaging)
 INDEX TERM: 186750-18-5P 186750-19-6P 186750-20-9P
 ROLE: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (in preparation of targeting optoacoustic contrast agent for thrombus; optoacoustic contrast agents and methods for their use in ultrasound and optical imaging)
 INDEX TERM: 2644-64-6, Dipalmitoylphosphatidylcholine 19698-29-4, Dipalmitoylphosphatidic acid 145035-97-8
 ROLE: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (perfluoropropane encapsulated in optoacoustic **liposomes** containing; optoacoustic contrast agents and methods for their use in ultrasound and optical imaging)
 INDEX TERM: 186750-20-9DP, conjugates with interleukin 2
 ROLE: ARG (Analytical reagent use); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
 (preparation of, as targeting optoacoustic contrast agent for thrombus; optoacoustic contrast agents and methods for their use in ultrasound and optical imaging)

INDEX TERM: 6066-82-6, N-Hydroxysuccinimide 108032-13-9 139729-28-5
 ROLE: RCT (Reactant); RACT (Reactant or reagent)
 (reaction of, in preparation of targeting optoacoustic contrast agent for thrombus; optoacoustic contrast agents and methods for their use in ultrasound and optical imaging)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD.


REFERENCE(S): (1) Levy; US 5283255 A 1994 HCAPLUS
 (2) Nakakjima, S; Proc SPIE-Int Soc Opt Eng 1995, V2371, P495 HCAPLUS
 (3) Unger; US 5846517 A 1998 HCAPLUS
 (4) Walters; US 5460800 A 1995
 (5) Warren, S; Proc Int Conf Lasers 1993, V15, P795

IT 151736-99-1

RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (as photoactive agent; optoacoustic contrast agents and methods for their use in ultrasound and optical imaging)

RN 151736-99-1 HCAPLUS

CN Boron, [(3 β)-cholest-5-en-3-yl 5-[(3,5-dimethyl-2H-pyrrol-2-ylidene)methyl]-1H-pyrrole-2-dodecanoato- κ N1, κ N5]difluoro-, (T-4)-(9CI) (CA INDEX NAME)




IT 2644-64-6, Dipalmitoylphosphatidylcholine 19698-29-4, Dipalmitoylphosphatidic acid


RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (perfluoropropane encapsulated in optoacoustic liposomes containing; optoacoustic contrast agents and methods for their use in ultrasound and optical imaging)

RN 2644-64-6 HCAPLUS

CN 3,5,9-Trioxa-4-phosphapentacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxohexadecyl)oxy]-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 19698-29-4 HCAPLUS

CN Hexadecanoic acid, 1-[(phosphonooxy)methyl]-1,2-ethanediyl ester (9CI)
(CA INDEX NAME)

L131 ANSWER 10 OF 26 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1999:570665 HCAPLUS

DOCUMENT NUMBER: 131:314159

ENTRY DATE: Entered STN: 09 Sep 1999

TITLE: Preparation and characterization of liposomal systems
entrapping the boronated compound o-
carboranylpropylamine

AUTHOR(S): Moraes, A. M.; Santana, M. H. A.; Carbonell, R. G.

CORPORATE SOURCE: Department Processos Biotecnologicos/FEQ/State
University of Campinas (UNICAMP), Campinas, 13081-970,
BrazilSOURCE: Journal of Microencapsulation (1999), 16(5),
647-664

CODEN: JOMIEF; ISSN: 0265-2048

PUBLISHER: Taylor & Francis Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

CLASSIFICATION: 63-6 (Pharmaceuticals)

Section cross-reference(s): 8

ABSTRACT:

Boron neutron capture therapy (BNCT) is based on the nuclear reaction that occurs when the stable isotope, ^{10}B , is irradiated with low-energy thermal neutrons to yield ionizing helium and lithium ions that are highly damaging and usually lethal to cells. The successful treatment of cancer by BNCT requires the selective concentration of ^{10}B within malignant tumors. Liposomes have been used

as therapeutic compound delivery vehicles for in vivo application, including several anticancer agents. The ability of the boron-containing compound, o-carboranylpropylamine chloride, to accumulate within **unilamellar** liposomes in response to a transmembrane pH gradient was evaluated.

Characterization of the systems obtained was performed for conventional and polyethylene glycol (PEG)-modified (stealth) liposomes, in terms of lipid and CPA contents, vesicle size and stability in detergent solns. CPA loading and vesicle stability can be controlled by the exptl. procedure. The loading of CPA into liposomes with average diams. of 100 nm was estimated at 13 000 mols./vesicle

for the most stable systems. CPA toxicity to normal human peripheral blood

lymphocytes and to adherent glioblastoma SK-MG-1 cells in vitro decreased as a result of the entrapment of CPA in liposomes.

SUPPL. TERM: liposome entrapment carboranylpropylamine; boron neutron capture therapy liposome; brain glioblastoma carboranylpropylamine liposome

INDEX TERM: Radiotherapy
(boron-neutron capture; preparation and characterization of liposomal systems entrapping carboranylpropylamine)

INDEX TERM: Neuroglia
(glioblastoma; preparation and characterization of liposomal systems entrapping carboranylpropylamine)

INDEX TERM: Drug delivery systems
(liposomes; preparation and characterization of liposomal systems entrapping carboranylpropylamine)

INDEX TERM: Brain, neoplasm
Encapsulation
Lymphocyte
(preparation and characterization of liposomal systems entrapping carboranylpropylamine)

INDEX TERM: 140662-87-9
ROLE: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(preparation and characterization of liposomal systems entrapping carboranylpropylamine)

INDEX TERM: 57-88-5, Cholesterol, biological studies
4539-70-2, DSPC 20255-95-2,
Dimyristoylphosphatidylethanolamine 211733-74-3
ROLE: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation and characterization of liposomal systems entrapping carboranylpropylamine)


REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD.

REFERENCE(S): (1) Autry, S; Advances in Neutron Capture Therapy 1997, VII, P347
(2) Barth, R; Cancer 1992, V70, P2995 MEDLINE
(3) Barth, R; Cancer Research 1990, V50, P1061 HCAPLUS
(4) Blume, G; Biochimica et Biophysica Acta 1990, V1029, P91 HCAPLUS
(5) Chen, P; Analytical Chemistry 1956, V28, P1756 HCAPLUS
(6) Edwards, K; Progress in Colloid & Polymer Science 1990, V82, P190 HCAPLUS
(7) Feakes, D; Proceedings of the National Academy of Science 1994, V91, P3029 HCAPLUS
(8) Feakes, D; Proceedings of the National Academy of Science 1995, V92, P1367 HCAPLUS
(9) Ford, N; Dynamic Light Scattering: Applications of Photon Correlation Spectroscopy 1985, P7
(10) Gabizon, A; Proceedings of the National Academy of Science USA 1988, V85, P6949 HCAPLUS
(11) Hall, I; Journal of Pharmaceutical Sciences 1985, V74, P755 HCAPLUS
(12) Hawthorne, F; Angewandte Chemie (International Edition in English) 1993, V32, P959
(13) Klibanov, A; FEBS Letters 1990, V268, P235 HCAPLUS
(14) Lasic, D; Biochimica et Biophysica Acta 1991, V1070, P187 HCAPLUS


- (15) Locher, H; American Journal of Roentgenological Radium Therapy 1936, V36, P1
- (16) Macdonald, R; Biochemica et Biophysica Acta 1991, V1061, P297 MEDLINE
- (17) Madden, T; Chemistry and Physics of Lipids 1990, V53, P37 HCAPLUS
- (18) Mayer, L; Biochimical et Biophysica Acta 1990, V1025, P143 HCAPLUS
- (19) Mayer, L; Chemistry and Physics of Lipids 1986, V40, P333 HCAPLUS
- (20) Mehta, S; Journal of Microencapsulation 1996, V13, P269 HCAPLUS
- (21) Moraes, A; Biofunctional Membranes 1996, P229
- (22) Murthy, K; Journal of Pharmaceutical Sciences 1970, V59, P1281 HCAPLUS
- (23) Papahadjopoulos, D; Proceedings of the National Academy of Science USA 1991, V88, P11460 HCAPLUS
- (24) Shelly, K; Proceedings of the National Academy of Science USA 1992, V89, P9039 HCAPLUS
- (25) Steffen, D; Master's Thesis, Department of Chemical Engineering, NCSU Raleigh 1993
- (26) Szoka, F; Annual Reviews in Biophysics and Bioengineering 1980, V9, P467 HCAPLUS
- (27) Woodle, M; Biophysical Journal 1992, V61, P902 HCAPLUS
- (28) Wu, N; Cancer Research 1993, V53, P3765 HCAPLUS
- (29) Yanagie, H; The British Journal of Cancer 1991, V63, P522 MEDLINE

IT 57-88-5, Cholesterol, biological studies 4539-70-2, DSPC
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (preparation and characterization of liposomal systems entrapping
carboranylpropylamine)
 RN 57-88-5 HCAPLUS
 CN Cholest-5-en-3-ol (3 β) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 4539-70-2 HCAPLUS
 CN 3,5,9-Trioxa-4-phosphaheptacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxooctadecyl)oxy]-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



L131 ANSWER 11 OF 26 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1999:253141 HCAPLUS

DOCUMENT NUMBER: 131:78261

ENTRY DATE: Entered STN: 26 Apr 1999

TITLE: Optimization of drug loading procedures and characterization of liposomal formulations of two novel agents intended for boron neutron capture therapy (BNCT)

AUTHOR(S): Johnsson, Markus; Bergstrand, Nill; Edwards, Katarina
CORPORATE SOURCE: Department of Physical Chemistry, Uppsala University, Uppsala, S-75121, Swed.

SOURCE: Journal of Liposome Research (1999), 9(1), 53-79

CODEN: JLREE7; ISSN: 0898-2104

PUBLISHER: Marcel Dekker, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

CLASSIFICATION: 63-5 (Pharmaceuticals)

ABSTRACT:

The characterization of 2 liposomal formulations of boronated DNA-interacting agents was performed. The 2 boronated drugs, WSA-Water Soluble Acridine and WSP-Water Soluble Phenanthridine, were encapsulated within **unilamellar** sterically stabilized liposomes with high drug-to-lipid ratios (up to 0.50:1 (mol:mol)), using transmembrane pH gradients. The steric stabilization of the liposomes was accomplished by the addition of DSPE-PEG(2000) (PEG-lipid) to DSPC/Cho lipid mixts. and the composition used was DSPC:Cho:DSPE-PEG 55:40:5 (mol%). The loading of the drugs resulted in drug precipitation in the liposomal aqueous *****core***** as observed by cryo-transmission electron microscopy. When pH gradients across the **bilayer** were used for remote loading of WSP or when ammonium sulfate gradients were used for remote loading of WSA, the formation of small **bilayer** fragments (disks) was induced. We present compelling evidence that the formation of disks is a consequence of precipitate growth in the liposomal interior. The precipitate growth causes some of the liposomes to rupture resulting in the above mentioned disk-formation and a substantial decrease in trapping efficiency. The in vitro stability of the drug loaded liposomes was excellent, both in buffer and in 25% human serum. For most of the formulations, the release of the drugs was below or around 10% after 24 h at 37°. The influence of initial internal pH and internal buffering capacity on release properties of WSA and WSP were investigated. The release profiles of the drugs can be controlled, to a large extent, by varying the composition of the internal liposomal aqueous phase.

SUPPL. TERM: liposome drug boron neutron capture therapy

INDEX TERM: Radiotherapy
(boron-neutron capture; optimization and characterization of liposomal formulations of drugs intended for boron

neutron capture therapy)
INDEX TERM: Drug delivery systems
(liposomes, **unilamellar**; optimization and
characterization of liposomal formulations of drugs
intended for boron neutron capture therapy)

INDEX TERM: Blood serum
Dissolution rate
Encapsulation
(optimization and characterization of liposomal
formulations of drugs intended for boron neutron capture
therapy)

INDEX TERM: 200135-21-3 229173-99-3
ROLE: PEP (Physical, engineering or chemical process); PRP
(Properties); THU (Therapeutic use); BIOL (Biological
study); PROC (Process); USES (Uses)
(optimization and characterization of liposomal
formulations of drugs intended for boron neutron capture
therapy)

INDEX TERM: **57-88-5**, Cholesterol, biological studies
816-94-4, DSPC 9002-92-0, Polyoxyethylene lauryl
ether 170931-04-1
ROLE: THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(optimization and characterization of liposomal
formulations of drugs intended for **boron**
neutron capture therapy)

REFERENCE COUNT: 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS
RECORD.

REFERENCE(S): (1) Allen, T; Biochim Biophys Acta 1991, V1066, P29 HCAPLUS
(2) Amselem, S; J Pharm Sci 1990, V79, P1045 HCAPLUS
(3) Bakker-Woudenberg, I; J Infect Dis 1993, V168, P164
(4) Bellare, J; J Electron Microsc Tech 1988, V10, P87
MEDLINE
(5) Bligh, E; Can J Biochem Physiol 1959, V37, P911 HCAPLUS
(6) Blume, G; Biochim Biophys Acta 1990, V1029, P91 HCAPLUS
(7) Blume, G; Biochim Biophys Acta 1993, V1146, P157 HCAPLUS
(8) Boman, N; Biochim Biophys Acta 1993, V1152, P253 HCAPLUS
(9) Cai, J; Tetrahedron Lett 1996, V37, P9283 HCAPLUS
(10) Ceh, B; Adv Drug Del Rev 1997, V24, P165 HCAPLUS
(11) Ceh, B; J Colloid Interface Sci 1997, V185, P9 HCAPLUS
(12) Ceh, B; Langmuir 1995, V11, P3356 HCAPLUS
(13) Chen, C; Bioconj Chem 1994, V5, P557 HCAPLUS
(14) Chen, W; Adv Drug Del Rev 1997, V26, P231 HCAPLUS
(15) Crenshaw, J; Biochemistry 1995, V34, P13682 HCAPLUS
(16) Cullis, P; Med Sci Res 1990, V18, P87 HCAPLUS
(17) Denny, W; J Med Chem 1982, V25, P276 HCAPLUS
(18) Dubochet, J; Q Rev Biophys 1988, V21, P129 MEDLINE
(19) Edwards, K; Biophys J 1997, V73, P258 HCAPLUS
(20) Edwards, K; J Colloid Interface Sci 1993, V161, P299
HCAPLUS
(21) Edwards, K; Langmuir 1992, V8, P824 HCAPLUS
(22) Edwards, K; Progr Colloid Polym Sci 1990, V82, P190
HCAPLUS
(23) Feakes, D; Proc Natl Acad Sci 1994, V91, P3029 HCAPLUS
(24) Forssen, E; Cancer Res 1992, V52, P3255 HCAPLUS
(25) Fromherz, P; Chem Phys Lett 1983, V94, P259 HCAPLUS
(26) Fry, D; Anal Biochem 1978, V90, P809 HCAPLUS
(27) Gabel, D; Radiat Res 1987, V111, P14 HCAPLUS
(28) Gabizon, A; Cancer Res 1990, V50, P6371 HCAPLUS
(29) Gedda, L; Bioconj Chem 1996, V7, P584 HCAPLUS


- (30) Gedda, L; Manuscript in preparation 1998
- (31) Ghaneolhosseini, H; Tetrahedron 1997, V53, P17519
HCAPLUS
- (32) Ghaneolhosseini, H; Tetrahedron 1998, V54, P3877
HCAPLUS
- (33) Haran, G; Biochim Biophys Acta 1993, V1151, P201
HCAPLUS
- (34) Harrigan, P; Biochim Biophys Acta 1993, V1149, P329
HCAPLUS
- (35) Hartman, T; Radiother Oncol 1994, V31, P61 HCAPLUS
- (36) Hawthorne, M; Angew Chem Int Ed Engl 1993, V32, P950
- (37) Hawthorne, M; J Neuro-Oncology 1997, V33, P53 MEDLINE
- (38) Lasic, D; Biochim Biophys Acta 1982, V692, P501 HCAPLUS
- (39) Lasic, D; Biochim Biophys Acta 1995, V1239, P145
HCAPLUS
- (40) Lasic, D; FEBS LETT 1992, V312, P255 HCAPLUS
- (41) Laster, B; Cancer Res 1991, V51, P4588 HCAPLUS
- (42) Lelkes, P; Biochim Biophys Acta 1984, V775, P395
HCAPLUS
- (43) Lerman, L; J Mol Biol 1961, V3, P18 HCAPLUS
- (44) Madden, T; Chem Phys Lip 1990, V53, P37 HCAPLUS
- (45) Mayer, L; Biochim Biophys Acta 1985, V816, P294 HCAPLUS
- (46) Mayer, L; Biochim Biophys Acta 1990, V1025, P143
HCAPLUS
- (47) Mehta, S; J Microencapsulation 1996, V13, P269 HCAPLUS
- (48) Oku, N; Biochim Biophys Acta 1992, V1126, P255 HCAPLUS
- (49) Papahadjopoulos, D; Proc Natl Acad Sci 1991, V88,
P11460 HCAPLUS
- (50) Ruiz, J; Biochim Biophys Acta 1988, V937, P127 HCAPLUS
- (51) Silvander, M; Accepted for publication in Chem Phys Lip
1998
- (52) Silvander, M; Anal Biochem 1996, V242, P40 HCAPLUS
- (53) Sobell, H; J Mol Biol 1977, V114, P333 HCAPLUS
- (54) Stewart, J; Anal Biochem 1980, V104, P10 HCAPLUS
- (55) Ueno, M; Biochemistry 1989, V28, P5631 HCAPLUS
- (56) Uster, P; FEBS LETT 1996, V386, P243 HCAPLUS
- (57) Wakelin, L; Mol Pharm 1974, V9, P544
- (58) Waring, M; Nature 1968, V219, P1320 HCAPLUS
- (59) Webb, M; Br J Cancer 1995, V72, P896 HCAPLUS
- (60) Woodle, M; Biochim Biophys Acta 1992, V1113, P171
HCAPLUS
- (61) Yanagie, H; Br J Cancer 1991, V63, P522 MEDLINE

IT 57-88-5, Cholesterol, biological studies 816-94-4, DSPC
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (optimization and characterization of liposomal formulations of drugs
 intended for boron neutron capture therapy)

RN 57-88-5 HCAPLUS

CN Cholest-5-en-3-ol (3 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 816-94-4 HCAPLUS

CN 3,5,9-Trioxa-4-phosphaheptacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxooctadecyl)oxy]-, inner salt, 4-oxide, (7R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L131 ANSWER 12 OF 26 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1996:289238 HCAPLUS

DOCUMENT NUMBER: 124:352448

ENTRY DATE: Entered STN: 16 May 1996

TITLE: Liposomal formulations containing sodium mercaptoundecahydrododecaborate (BSH) for boron neutron capture therapy

AUTHOR(S): Mehta, S. C.; Lai, J. C. K.; Lu, D. R.

CORPORATE SOURCE: Dep. Pharmaceuticals, College Pharmacy, Univ. Georgia, Athens, GA, 30602, USA

SOURCE: Journal of Microencapsulation (1996), 13(3), 269-279

CODEN: JOMIEF; ISSN: 0265-2048

PUBLISHER: Taylor & Francis

DOCUMENT TYPE: Journal

LANGUAGE: English

CLASSIFICATION: 63-5 (Pharmaceuticals)

Section cross-reference(s): 8

ABSTRACT:

Sodium mercaptoundecahydrododecaborate or BSH is a compound most widely used for boron neutron capture therapy (BNCT). Liposome formulations containing BSH, with or without steric stabilization, were prepared as potential agents for delivery of boron compds. for BNCT. Liposomes composed of DPPC/CHOL in a molar ratio 1:1 (PEG concentration: 5 mol%) were prepared having an average diameter in the range of

100-110 nm 200 μ L of liposomes (1.88 mg phospholipid/mouse and 3.5-5.8 mg BSH/kg body weight) were injected in mice via the tail vein. Both types of

liposomes resulted in a significant improvement in the circulation time of BSH compared to that obtained previously after injecting free BSH. The mean percent injected BSH remaining in circulation at the end of 24 h was 19% for the PEG-liposomes compared to the corresponding value of 7% for the conventional liposomes. The mean percent uptake by the liver and spleen was not significantly different for the 2 types of liposomes; the blood/RES ratios were higher for the PEG-liposomes at all time points indicating that a higher fraction of injected BSH was available in circulation. The PEG-liposomes could be further explored as a means of enhance boron drug delivery to tumor cells for BNCT.

SUPPL. TERM: liposome mercaptoundecahydrododecaborate boron neutron capture therapy

INDEX TERM: Blood
Liver
Reticuloendothelial system
Spleen
(liposomes containing mercaptoundecahydrododecaborate for boron neutron capture therapy)

INDEX TERM: **Radiotherapy**
(boron-neutron capture, liposomes containing mercaptoundecahydrododecaborate for boron neutron capture therapy)

INDEX TERM: **Pharmaceutical** dosage forms
(liposomes, liposomes containing mercaptoundecahydrododecaborate for boron neutron capture therapy)

INDEX TERM: 144885-51-8, Sodium mercaptoundecahydrododecaborate
ROLE: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(liposomes containing mercaptoundecahydrododecaborate for boron neutron capture therapy)


INDEX TERM: 57-88-5, CHOLesterol, biological studies
2644-64-6, DPPC 5681-36-7D, Dipalmitoylphosphatidylethanolamine, reaction products with PEG 25322-68-3D, PEG, reaction products with DPPE
ROLE: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liposomes containing mercaptoundecahydrododecaborate for boron neutron capture therapy)

IT 57-88-5, CHOLesterol, biological studies 2644-64-6, DPPC 5681-36-7D, Dipalmitoylphosphatidylethanolamine, reaction products with PEG
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liposomes containing mercaptoundecahydrododecaborate for boron neutron capture therapy)

RN 57-88-5 HCAPLUS


CN Cholest-5-en-3-ol (3 β) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 2644-64-6 HCAPLUS

CN 3,5,9-Trioxa-4-phosphapentacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxohexadecyl)oxy]-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 5681-36-7 HCAPLUS

CN Hexadecanoic acid, 1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)



L131 ANSWER 13 OF 26 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1996:423728 HCAPLUS

DOCUMENT NUMBER: 125:123458

ENTRY DATE: Entered STN: 18 Jul 1996

TITLE: Characterization of liposomal systems entrapping boron-containing compounds in response to pH gradients

AUTHOR(S): Moraes, Angela M.; Santana, Maria Helena A.; Carbonell, Ruben G.

CORPORATE SOURCE: Dept. Proc. Quimicos, State University Campinas, Campinas, 13083-000, Brazil

SOURCE: Biofunctional Membranes, [Proceedings of the International Conference on Biofunctional Membranes], Lexington, Ky., Apr. 9-11, 1995 (1996),

Meeting Date 1995, 259-275. Editor(s): Butterfield,
D. Allan. Plenum: New York, N. Y.
CODEN: 63AXAU


DOCUMENT TYPE: Conference
LANGUAGE: English
CLASSIFICATION: 63-5 (Pharmaceuticals)
Section cross-reference(s): 8

ABSTRACT:

Boron neutron capture therapy (BNCT) is based on the nuclear reaction that occurs when a stable isotope, boron-10, is irradiated with low-energy thermal neutrons to yield ionizing helium and lithium ions that are highly damaging and usually lethal to cells. The successful treatment of cancer by BNCT requires the selective concentration of boron-10 within malignant tumors. Liposomes have been used as drug delivery vehicles for in vivo application, including several anticancer agents. The ability of two boron-containing compds., l-p-borono-phenylalanine (BPA) HCl and o-carboranylpropylamine chloride (CPA) to accumulate within **unilamellar** liposomes passively and in response to a transmembrane pH gradient are compared. Characterization of the obtained systems is performed for conventional and polyethylene glycol (PEG)-modified (stealth) liposomes, in terms of lipid and drug contents, vesicle size and stability. The results indicate that BPA can be successfully encapsulated in conventional liposomes by passive loading, while the active loading approach is more suitable for the entrapment of CPA.


SUPPL. TERM: boron compd liposome encapsulation pH; neutron capture
radiotherapy liposome boron compd
INDEX TERM: Encapsulation
Neoplasm
Particle size
(liposomes encapsulation of boron-containing compds. in
response to pH gradients for neutron capture therapy)
INDEX TERM: Pharmaceutical dosage forms
(liposomes, liposomes encapsulation of boron-containing
compds. in response to pH gradients for neutron capture
therapy)
INDEX TERM: Radiotherapy
(neutron capture, liposomes encapsulation of boron-containing
compds. in response to pH gradients for neutron capture
therapy)
INDEX TERM: 57-88-5, Cholesterol, biological studies 4539-70-2,
Distearoyl phosphatidylcholine
7440-42-8D, Boron, compds. 20255-95-2, Dimyristoyl
phosphatidylethanolamine 76410-59-8 140662-87-9
179484-10-7
ROLE: THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(liposomes encapsulation of **boron**-containing
compds. in response to pH gradients for neutron capture
therapy)
IT 57-88-5, Cholesterol, biological studies 4539-70-2,
Distearoyl phosphatidylcholine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liposomes encapsulation of **boron**-containing compds. in response
to pH gradients for neutron capture therapy)
RN 57-88-5 HCAPLUS
CN Cholest-5-en-3-ol (3 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 4539-70-2 HCAPLUS

CN 3,5,9-Trioxa-4-phosphaheptacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxooctadecyl)oxy]-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



L131 ANSWER 14 OF 26 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1994:3825 HCAPLUS

DOCUMENT NUMBER: 120:3825

ENTRY DATE: Entered STN: 08 Jan 1994

TITLE: Use of fluorescent cholesteryl ester
microemulsions in cholesteryl ester transfer
protein assays

AUTHOR(S): Bisgaier, Charles L.; Minton, Laura L.; Essenburg,
Arnold D.; White, Andrew; Homan, Reynold
CORPORATE SOURCE: Dep. Pharmacol., Parke-Davis Pharm. Res., Ann Arbor,
MI, 48105, USA

SOURCE: Journal of Lipid Research (1993), 34(9),
1625-34
CODEN: JLPRAW; ISSN: 0022-2275

DOCUMENT TYPE: Journal

LANGUAGE: English

CLASSIFICATION: 9-5 (Biochemical Methods)

ABSTRACT:

In the present report the authors describe a simple and practical method to assess CETP activity in a defined system by use of **microemulsions** containing a fluorescent cholesteryl ester analog. The **microemulsions** are stable, simple to prepare, and can be made to defined composition. Initial transfer rates are easily determined by monitoring changes in fluorescence. The authors have used the fluorescent cholesteryl ester analog, cholesteryl 4,4-difluoro-5,7-dimethyl-4-bora-3 α ,4 α -diazaphthalene-3-indacenedodecanoate (BODIPY-CE), to demonstrate the utility of this assay. The assay takes advantage of the concentration-dependent self-quenching of BODIPY-CE, when this analog is incorporated into **microemulsions**. The authors have used this new assay to demonstrate fluorescent lipid transfer facilitated by rabbit

and human d>1.21 g/mL plasma fraction and recombinant human CETP. A known inhibitory monoclonal antibody (Mab) to human CETP blocked PODIPY-CE transfer in a dose-dependent manner. The authors have also used BODIPY-CE ***microemulsions*** to measure CETP activity in whole plasma.

SUPPL. TERM: cholesteryl ester transfer protein detn fluorometry; CETP protein **microemulsion** cholesterol ester fluorometry

INDEX TERM: Blood analysis
(cholesteryl ester transfer protein determination in human and laboratory animal, with **microemulsions** containing fluorescent cholesteryl ester)

INDEX TERM: **Lipids**, uses
ROLE: USES (Uses)
(**microemulsions**, for cholesteryl ester transfer protein determination, cholesteryl ester fluorescent analogs in)

INDEX TERM: Proteins, specific or class
ROLE: ANT (Analyte); ANST (Analytical study)
(cholesterol ester-exchanging, determination of, of human and laboratory animal plasma, fluorescent cholesteryl ester **microemulsions** in)


INDEX TERM: **Emulsions**
(micro-, **lipid**, cholesterol ester fluorescent analogs in, for cholesteryl ester transfer protein determination)

INDEX TERM: 57-88-5D, Cholesterol, esters, fluorescent **151736-99-1**
ROLE: ANST (Analytical study)
(in cholesteryl ester transfer protein determination of plasma, in **microemulsions**)

IT **151736-99-1**
RL: ANST (Analytical study)
(in cholesteryl ester transfer protein determination of plasma, in **microemulsions**)

RN 151736-99-1 HCAPLUS

CN Boron, [(3 β)-cholest-5-en-3-yl 5-[(3,5-dimethyl-2H-pyrrol-2-ylidene)methyl]-1H-pyrrole-2-dodecanoato- κ N1, κ N5]difluoro-, (T-4)- (9CI) (CA INDEX NAME)



L131 ANSWER 15 OF 26 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1994:37930 HCAPLUS

DOCUMENT NUMBER: 120:37930

ENTRY DATE: Entered STN: 22 Jan 1994

TITLE: Characterization of biotinylated liposomes for in vivo targeting applications

AUTHOR(S): Loughrey, Helen C.; Ferraretto, Anita; Cannon, Ann-Marie; Acerbis, Giulia; Sudati, Francesco; Bottioli, Giovanni; Masserini, Massimo; Soria, Marco R.

CORPORATE SOURCE: Department of Biochemistry, University College Galway, Galway, Ire.

SOURCE: FEBS Letters (1993), 332(1-2), 183-8

CODEN: FEBLAL; ISSN: 0014-5793

DOCUMENT TYPE: Journal

LANGUAGE: English

CLASSIFICATION: 63-5 (Pharmaceuticals)


Section cross-reference(s): 1

ABSTRACT:

Liposomes containing monosialoganglioside (GM1) or polyethylene glycol (PEG) lipid derivs. have prolonged circulation in the blood. This favors **liposome** extravasation to tumor sites. In this report it is shown that inclusion of GM1, PEG550-DPPE or PEG2000-DPPE in **liposomes** containing biotin-DPPE significantly diminished the ability of vesicles to bind to **streptavidin** in vitro. Steric inhibition due to the bulky head group of these **lipids** was least for biotin-DPPE **liposomes** containing GM1. Biodistribution studies in C26 tumor-bearing mice showed that GM1-**liposomes** containing small amts. of biotin-DPPE have long circulation life-times in the blood. Using fluorescent microscopic techniques, **liposomes** containing both GM1 and biotin-DPPE were detected within extra-vascular spaces in tumors. In addition it was shown that biotin-DPPE in GM1-**liposomes** bound **streptavidin** in situ. These results suggest that GM1-**liposomes** containing biotin-DPPE have potential use as diagnostic or therapeutic reagents in pre-targeting applications dependent on the high-affinity interaction of biotin with **streptavidin**.

SUPPL. TERM: biotinylated liposome streptavidin

binding tumor targeting; monosialoganglioside GM1
 biotinylated **liposome streptavidin** tumor
 INDEX TERM: Neoplasm
 (biotinylated **liposomes** targeting to,
streptavidin binding in relation to)
 INDEX TERM: **Phosphatidylcholines, biological studies**
 ROLE: BIOL (Biological study)
 (egg yolk, biotinylated **liposomes** containing,
streptavidin binding to, tumor targeting in
 relation to)
 INDEX TERM: Pharmaceutical dosage forms
 (**liposomes**, large unilamellar,
 biotinylated, **streptavidin** binding to, tumor
 targeting in relation to)
 INDEX TERM: 9013-20-1, **Streptavidin**???
 ROLE: PROC (Process)
 (binding of, to biotinylated **liposomes**, tumor
 targeting in relation to)
 INDEX TERM: 57-88-5, Cholest-5-en-3-ol (3 β)-, biological studies
 37758-47-7, Ganglioside GM1 151911-45-4
 ROLE: BIOL (Biological study)
 (biotinylated **liposomes** containing,
streptavidin binding to, tumor targeting in
 relation to)
 INDEX TERM: 116643-36-8 151835-78-8
 ROLE: BIOL (Biological study)
 (**liposomes** containing, **streptavidin**
 binding to, tumor targeting in relation to)
 IT 37758-47-7, Ganglioside GM1 151911-45-4
 RL: BIOL (Biological study)
 (biotinylated **liposomes** containing, **streptavidin**
 binding to, tumor targeting in relation to)
 RN 37758-47-7 HCAPLUS
 CN Ganglioside GM1 (9CI) (CA INDEX NAME)
 *** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
 RN 151911-45-4 HCAPLUS
 CN Boron, [(3 β)-cholest-5-en-3-yl 2-[(3,5-dimethyl-1H-pyrrol-2-yl-
 κ N)methylene]-2H-pyrrole-5-dodecanoato- κ N1]difluoro-, (T-4)-
 (9CI) (CA INDEX NAME)



L131 ANSWER 16 OF 26 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1990:213162 HCAPLUS

DOCUMENT NUMBER: 112:213162

ENTRY DATE: Entered STN: 09 Jun 1990

TITLE: Application of boronated anti CEA-immunoliposome to boron neutron capture therapy

AUTHOR(S): Yanagie, Hironobu; Fujii, Yuzo; Takahashi, Tsukasa; Sekiguchi, Morimasa; Uchida, Hisanori; Nariuchi, Hideo; Tomita, Toshio; Yasuda, Tatuji; Kobayashi, Hisao; et al.

CORPORATE SOURCE: Inst. Med. Sci., Univ. Tokyo, Tokyo, 108, Japan

SOURCE: Kyoto Daigaku Genshiro Jikkensho Gakujutsu Koenkai

Koen Yoshishu (1990), 24, 71-7

CODEN: KDGYDY; ISSN: 0287-9131

DOCUMENT TYPE: Journal

LANGUAGE: Japanese

CLASSIFICATION: 8-9 (Radiation Biochemistry)

Section cross-reference(s): 14, 63

ABSTRACT:

A selective drug delivery system for B-neutron capture therapy (BNCT) of noncerebral tumors was established, consisting of anti-CEA monoclonal antibody (4 mg/mL) conjugated with liposomes which contained 10B-compound (623 ppm) inside. The immunoliposomes attached to CEA-producing human pancreatic carcinoma cells, AsPC-1, and suppressed the cell growth in vitro upon thermal neutron irradiation ($1 + 10^{12}$ neutrons/cm² flux). The suppression was dependent on the concentration of 10B-compound within liposomes and the d. of antibody conjugated to liposome. These results suggested that immunoliposomes containing 10B-compound could provide a selective and efficient carrier of B atoms to target tumor cells for BNCT.

SUPPL. TERM: boron neutron capture radiotherapy tumor; antibody liposome
boron neutron capture therapy

INDEX TERM: Neoplasm, toxic chemical and physical damage
(boron compound-containing immunoliposomes damage to, in
boron-neutron capture radiotherapy)

INDEX TERM: Neoplasm inhibitors

(boron compound-containing immunoliposomes, in boron-neutron capture radiotherapy)

INDEX TERM: **Phosphatidylcholines, biological studies**
 ROLE: BIOL (Biological study)
 (immunoliposomes containing, for boron-neutron capture radiotherapy of tumors)

INDEX TERM: **Antigens**
 ROLE: BIOL (Biological study)
 (CEA (carcinoembryonic antigen), monoclonal antibodies to, in boronated liposomes for boron-neutron capture radiotherapy of tumors)

INDEX TERM: **Pancreas, neoplasm**
 (carcinoma, boron compound-containing immunoliposomes damage to, in boron-neutron capture radiotherapy)

INDEX TERM: **Radiotherapy**
 (immuno-, boron-neutron capture, of tumors, with boron compound-containing immunoliposomes)

INDEX TERM: **Pharmaceutical dosage forms**
 (liposomes, containing monoclonal antibodies, for boron-neutron capture radiotherapy of tumors)

INDEX TERM: **Antibodies**
 ROLE: BIOL (Biological study)
 (monoclonal, against carcinoembryonic antigen, in liposomes containing boron compds., for boron-neutron capture radiotherapy of tumors)


INDEX TERM: **57-88-5, Cholesterol, biological studies**
 109742-44-1 126938-07-6
 ROLE: BIOL (Biological study)
 (immunoliposomes containing, for boron-neutron capture radiotherapy of tumors)

INDEX TERM: 12586-31-1
 ROLE: BIOL (Biological study)
 (radiotherapy, immuno-, boron-neutron capture, of tumors, with boron compound-containing immunoliposomes)

IT **57-88-5, Cholesterol, biological studies**
 RL: BIOL (Biological study)
 (immunoliposomes containing, for boron-neutron capture radiotherapy of tumors)

RN 57-88-5 HCAPLUS
 CN Cholest-5-en-3-ol (3 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d 1131 ibib ab 17-25

YOU HAVE REQUESTED DATA FROM FILE 'USPATFULL, HCAPLUS, BIOSIS' - CONTINUE? (Y)/N:y

L131 ANSWER 17 OF 26 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
DUPLICATE 1

ACCESSION NUMBER: 2002:348359 BIOSIS
DOCUMENT NUMBER: PREV200200348359
TITLE: **Carborane** containing **cholesterol**, a new
type of molecule for targeted **boron drug**
delivery.
AUTHOR(S): Lu, Donghao Robert [Inventor, Reprint author]; Ji, Bing
Qing [Inventor]
CORPORATE SOURCE: Athens, GA, USA
ASSIGNEE: The University of Georgia Research Foundation,
Inc., Athens, GA, USA
PATENT INFORMATION: US 6392068 May 21, 2002
SOURCE: Official Gazette of the United States Patent and Trademark
Office Patents, (May 21, 2002) Vol. 1258, No. 3.
<http://www.uspto.gov/web/menu/patdata.html>. e-file.
CODEN: OGUPE7. ISSN: 0098-1133.
DOCUMENT TYPE: Patent
LANGUAGE: English
ENTRY DATE: Entered STN: 19 Jun 2002
Last Updated on STN: 19 Jun 2002

AB The present invention relates to novel **carborane**
cholesterol analogs and their use in the treatment of tumor and
cancers in humans, and in particular to the treatment of human brain
tumors. **Pharmaceutical** compositions and methods of using these
compositions in the treatment of tumors and cancer are other aspects of
the present invention.

L131 ANSWER 18 OF 26 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN

ACCESSION NUMBER: 2004:172437 BIOSIS
DOCUMENT NUMBER: PREV200400173455
TITLE: In vitro uptake of a new **cholesteryl**
carborane ester compound by human glioma cell
lines.
AUTHOR(S): Peacock, Gina; Sidwell, Richard; Pan, Guangliang; Oie,
Svein; Lu, D. Robert [Reprint Author]
CORPORATE SOURCE: Department of Pharmaceutical Sciences, School of Pharmacy,
Temple University, 3307 North Broad Street, Philadelphia,
PA, 19140, USA
rlu@temple.edu
SOURCE: Journal of Pharmaceutical Sciences, (January 2004) Vol. 93,
No. 1, pp. 13-19. print.
CODEN: JPMSAE. ISSN: 0022-3549.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 31 Mar 2004
Last Updated on STN: 31 Mar 2004

AB The cellular uptake and retention of a new **cholesteryl**
carborane ester compound, **cholesteryl**
1,12-dicarba-closo-dodecaboranel-carboxylate (BCH), by two human
glioma cell lines, glioblastoma multiforme SF-763 and SF-767, was
evaluated. BCH, which is an extremely **hydrophobic** compound, was
formulated into liposomes and incubated with two human glioma tumor cell
lines and one human normal neuron cell line. The amount of BCH uptake by
the cells was measured by high performance liquid chromatography. The
effects of BCH concentration in the culture medium and the incubation time
on the cellular uptake of BCH were studied. In addition, BCH uptake by

tumor cells was examined in the presence and absence of lipoprotein in the culture medium. It was found that the amount of BCH taken by the glioma cell lines was much more (up to 14 times) than that by the normal neuron cell line. The cellular uptake of BCH was related to the amount of BCH in the medium as well as the incubation time. The cellular uptake of BCH by SF-763 and SF-767 cells after 16 h of incubation was 283.3+-38.9 and 264.0+-36.5 mug **boron**/g cells, respectively. The majority of BCH taken up in tumor cells was retained after the subsequent incubation. In the presence of lipoprotein, the cellular uptake of BCH by SF-767 tumor cells was about four times as much as that in the absence of lipoprotein. In conclusion, the cellular uptake of BCH by glioma cells was about 14 times higher than by normal neuron cells. The uptake in glioma cells was up to 10 times higher than that required for successful cancer treatment and BCH was well retained in the tumor cells. Lipoprotein seemed to have an important role in the BCH uptake by glioma cells.

L131 ANSWER 19 OF 26 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN

ACCESSION NUMBER: 2003:274501 BIOSIS

DOCUMENT NUMBER: PREV200300274501

TITLE: Synthesis, preformulation and liposomal formulation of **cholesteryl carborane** esters with various fatty chains.

AUTHOR(S): Alanazi, Fars; Li, Hengguang; Halpern, David S.; Oie, Svein; Lu, D. Robert [Reprint Author]

CORPORATE SOURCE: Department of Pharmaceutical and Biomedical Science, College of Pharmacy, University of Georgia, Athens, GA, 30602, USA

rlu@rx.uga.edu

SOURCE: International Journal of Pharmaceutics (Kidlington), (14 April 2003) Vol. 255, No. 1-2, pp. 189-197. print. ISSN: 0378-5173 (ISSN print).

DOCUMENT TYPE: Article

LANGUAGE: English

ENTRY DATE: Entered STN: 11 Jun 2003

Last Updated on STN: 11 Jun 2003

AB The elevated expression of LDL receptor on tumor cells provides one attractive approach for targeted drug delivery to tumor cells. Suitable antitumor compounds, however, need to be synthesized and developed which mimic the native **cholesteryl** esters (as major constituent of LDL) in chemical structure for targeted delivery to tumor cells through the over-expressed LDL receptors. In the present study, new antitumor compounds were designed containing **cholesterol**, fatty chain and **carborane** which is used as the antitumor unit. Three new compounds were synthesized with a three-step reaction scheme. Similar to the native **cholesteryl** esters, these compounds are extremely **hydrophobic** and, before any further biological studies, suitable liposomal formulations for these new compounds are required. Various liposomal formulations as well as the preformulation characterization of these new compounds were thus examined. The incorporation efficiency of the compounds in liposomes was found to vary significantly depending on the type of fatty chain attached and the ratio of **cholesterol** :phospholipid used as the excipients of liposomal formulation.

L131 ANSWER 20 OF 26 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN

ACCESSION NUMBER: 2003:411356 BIOSIS

DOCUMENT NUMBER: PREV200300411356

TITLE: Liposomes from novel carborane-containing lipids for **boron neutron capture** therapy.

AUTHOR(S): Li, Tiejun [Reprint Author]; Thomas, Jason [Reprint Author]; Hawthorne, M. Frederick [Reprint Author]

CORPORATE SOURCE: Department of Chemistry and Biochemistry, University of California, 405 Hilgard Avenue, Los Angeles, CA, 90095-1569, USA
tli@chem.ucla.edu

SOURCE: Abstracts of Papers American Chemical Society, (2003) Vol. 225, No. 1-2, pp. INOR 161. print.
Meeting Info.: 225th American Chemical Society (ACS) National Meeting. New Orleans, LA, USA. March 23-27, 2003.
American Chemical Society.
ISSN: 0065-7727 (ISSN print).

DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)

LANGUAGE: English

ENTRY DATE: Entered STN: 10 Sep 2003
Last Updated on STN: 10 Sep 2003

L131 ANSWER 21 OF 26 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN

ACCESSION NUMBER: 2002:505479 BIOSIS

DOCUMENT NUMBER: PREV200200505479

TITLE: Synthesis of **cholesterol-carborane** conjugate for targeted **drug delivery**.

AUTHOR(S): Ji, Bingqing; Peacock, Gina; Lu, D. Robert [Reprint author]

CORPORATE SOURCE: Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, GA, 30602, USA
rlu@rx.uga.edu

SOURCE: Bioorganic and Medicinal Chemistry Letters, (September, 2002) Vol. 12, No. 17, pp. 2455-2458. print.
CODEN: BMCLE8. ISSN: 0960-894X.

DOCUMENT TYPE: Article

LANGUAGE: English

ENTRY DATE: Entered STN: 25 Sep 2002
Last Updated on STN: 25 Sep 2002

AB The **cholesterol-carborane** conjugate has been designed and synthesized to selectively deliver **boron** to tumor cells by means of reconstituted low-density lipoprotein. The chemical stability and cytotoxicity of the new compound have been examined. Several methods have been evaluated for incorporation of the compound into LDL.

L131 ANSWER 22 OF 26 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN

ACCESSION NUMBER: 2002:384246 BIOSIS

DOCUMENT NUMBER: PREV200200384246

TITLE: **VLDL**-resembling phospholipid-submicron **emulsion** for cholesterol-based drug targeting.

AUTHOR(S): Shower, Mohannad; Greenspan, Phillip; Oie, Svein; Lu, D. Robert [Reprint author]

CORPORATE SOURCE: Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, GA, 30602, USA
rlu@rx.uga.edu

SOURCE: Journal of Pharmaceutical Sciences, (June, 2002) Vol. 91, No. 6, pp. 1405-1413. print.
CODEN: JPMSAE. ISSN: 0022-3549.

DOCUMENT TYPE: Article

LANGUAGE: English

ENTRY DATE: Entered STN: 10 Jul 2002
Last Updated on STN: 10 Jul 2002

AB The objective of the current study was to develop and evaluate **VLDL**-resembling phospholipid-submicron **emulsion** (PSME) as a carrier system for new **cholesterol**-based compounds for targeted

delivery to cancer cells. BCH, a **boronated cholesterol** compound, was originally developed in our laboratory to mimic the **cholesterol** esters present in the LDL and to follow a similar pathway of **cholesterol** transport into the rapidly dividing cancer cells. The VLDL-resembling system was then designed to solubilize BCH, facilitate the interaction with LDL, and thus assist the BCH delivery to cancer cells. BCH-containing PSME was prepared by sonication. Chemical compositions and particle sizes of different PSME fractions were determined. The lipid structure of PSME and location of BCH in the formulation were assessed based on experimental results. Density gradient ultracentrifugation fractionated the **emulsion** into three particle-size populations with structures and compositions resembling native VLDL. In vitro interaction between PSME, and LDL was evident by agarose electrophoresis, as both formed a single band with an intermediate mobility. The transfer of BCH from PSME to LDL was also observed in the presence of other serum components including serum proteins. Cell culture data showed sufficient uptake of BCH in rat 9L glioma cells (>50 mug **boron**/g cells). In conclusion, this system has the capability to incorporate the **cholesterol**-based compound, interact with native LDL, and assist the delivery of this compound into cancer cells in vitro.

L131 ANSWER 23 OF 26 BIOSIS. COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN

ACCESSION NUMBER: 1997:30890 BIOSIS

DOCUMENT NUMBER: PREV199799337293

TITLE: Selective uptake of boronated low-density lipoprotein in melanoma **xenografts** achieved by diet supplementation.

AUTHOR(S): Setiawan, Y.; Moore, D. E. [Reprint author]; Allen, B. J.

CORPORATE SOURCE: Dep. Pharmacy, University Sydney, Sydney, NSW 2006, Australia

SOURCE: British Journal of Cancer, (1996) Vol. 74, No. 11, pp. 1705-1708.

CODEN: BJCAAI. ISSN: 0007-0920.

DOCUMENT TYPE: Article

LANGUAGE: English

ENTRY DATE: Entered STN: 28 Jan 1997

Last Updated on STN: 28 Jan 1997

AB The lipid **core** of human plasma low-density lipoprotein (LDL) was extracted using hexane and the LDL reconstituted with the addition of n-octyl-carborane. Biodistribution studies of the **boronated** LDL were performed in BALB/c mice bearing subcutaneous Harding-Passey melanoma xenografts. When diet supplementation with coconut oil and **cholesterol** for 21 days and regular dosing with hydrocortisone for 7 days before the studies was used to down-regulate the liver LDL receptors and the adrenal receptors, respectively, the tumour-blood **boron** concentration ratio of 5:1 was achieved.

L131 ANSWER 24 OF 26 BIOSIS. COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN

ACCESSION NUMBER: 1995:209048 BIOSIS

DOCUMENT NUMBER: PREV199598223348

TITLE: Selective boron delivery to **murine tumors** by lipophilic species incorporated in the membranes of **unilamellar** liposomes.

AUTHOR(S): Feakes, Debra A.; Shelly, Kenneth; Hawthorne, M. Frederick [Reprint author]

CORPORATE SOURCE: Dep. Chem. Biochem., Univ. California Los Angeles, Los Angeles, CA 90024, USA

SOURCE: Proceedings of the National Academy of Sciences of the United States of America, (1995) Vol. 92, No. 5, pp. 1367-1370.

CODEN: PNASA6. ISSN: 0027-8424.

DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 23 May 1995
Last Updated on STN: 23 May 1995

AB The nido-carborane species K(nido-7-CH-3(CH-2)-15-7,8-C-2B-9H-11) has been synthesized for use as an addend for the **bilayer** membrane of liposomes. Small **unilamellar** vesicles, composed of distearoylphosphatidylcholine/**cholesterol**, 1:1, and incorporating K(nido-7-CH-3(CH-2)-15-7,8-C-2B-9H-11) in the **bilayer**, have been investigated in vivo. The time-course biodistribution of **boron** delivered by these liposomes was determined by inductively coupled plasma-atomic emission spectroscopy analyses after the injection of liposomal suspensions in BALB/c mice bearing EMT6 mammary adenocarcinomas. At the low injected doses normally used (approx 5-10 mg of **boron** per kg of body weight), peak tumor **boron** concentrations of approx 35 mu-g of **boron** per g of tissue and tumor/blood **boron** ratios of approx 8 were achieved. These values are sufficiently high for the successful application of **boron** neutron capture therapy. The **bilayer**-embedded **boron** compound may provide the sole **boron** source or, alternatively, a concentrated aqueous solution of a **hydrophilic boron** compound may also be encapsulated within the liposomes to provide a dose enhancement. Thus, the incorporation of both K(nido-7-CH-3(CH-2)-15-7,8-C-2B-9H-11) and the **hydrophilic** species, Na-3(1-(2'-B-10H-9)-2-NH-3B-10H-8), within the same liposomes demonstrated significantly enhanced biodistribution characteristics, exemplified by maximum tumor **boron** concentrations of approx 50 mu-g of **boron** per g of tissue and tumor/blood **boron** ratios of approx 6.

L131 ANSWER 25 OF 26 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN

ACCESSION NUMBER: 1993:6640 BIOSIS

DOCUMENT NUMBER: PREV199395006640

TITLE: Model studies directed toward the **boron**
neutron-capture therapy of cancer: Boron
delivery to **murine tumors** with
liposomes.

AUTHOR(S): Shelly, Kenneth; Feakes, D. A.; Hawthorne, M. Frederick
[Reprint author]; Schmidt, Paul G.; Krisch, Teresa A.;
Bauer, William F.

CORPORATE SOURCE: Dep. Chemistry Biochemistry, University California, Los
Angeles, Calif. 90024, USA

SOURCE: Proceedings of the National Academy of Sciences of the
United States of America, (1992) Vol. 89, No. 19, pp.
9039-9043.

CODEN: PNASA6. ISSN: 0027-8424.

DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 10 Dec 1992
Last Updated on STN: 13 Dec 1992

AB The successful treatment of cancer by **boron** neutron-capture therapy (BNCT) requires the selective concentration of **boron-10** within malignant tumors. The potential of liposomes to deliver **boron**-rich compounds to tumors has been assessed by the examination of the biodistribution of **boron** delivered by liposomes in tumor-bearing mice. Small **unilamellar** vesicles with mean diameters of 70 nm or less, composed of a pure synthetic phospholipid (distearoyl phosphatidylcholine) and **cholesterol**, have been found to stably encapsulate high concentrations of water-soluble

ionic **boron** compounds. The hydrolytically stable **borane** anions B-10H-10-2-, B-12H-11SH-2- B-20H-17OH-4-, B-20H1-9-3-, and the normal form and photoisomer of B-20H-18-2- were encapsulated in liposomes as their soluble sodium salts. The tissue concentration of **boron** in tumor-bearing mice was measured at several time points over 48 h after i.v. injection of **emulsions** of liposomes containing the **borane** anions. Although the **boron** compounds used do not exhibited an affinity for tumors and are normally rapidly cleared from the body, liposomes were observed to selectively deliver the **borane** anions to tumors. The highest tumor concentrations achieved reached the therapeutic range (gt 15 μ -g of **boron** per g of tumor) while maintaining high tumor-**boron**/blood-**boron** ratios (gt 3). The most favorable results were obtained with the two isomers of B-20H-18-2-. These **boron** compounds have the capability to react with intracellular components after they have been deposited within tumor cells by the liposome, thereby preventing the **borane** ion from being released into blood.

=> d l131 ibib ab kwic 26

YOU HAVE REQUESTED DATA FROM FILE 'USPATFULL, HCAPLUS, BIOSIS' - CONTINUE? (Y)/N:Y

L131 ANSWER 26 OF 26 USPATFULL on STN

ACCESSION NUMBER: 2000:127960 USPATFULL
 TITLE: Optoacoustic contrast agents and methods for their use
 INVENTOR(S): Unger, Evan C., Tucson, AZ, United States
 Wu, Yunqiu, Tucson, AZ, United States
 PATENT ASSIGNEE(S): Imarx Pharmaceutical Corp., Tucson, AZ, United States
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6123923		20000926
APPLICATION INFO.:	US 1997-993165		19971218 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-46379P	19970513 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Dees, Jose' G.	
ASSISTANT EXAMINER:	Sharareh, Shahnam	
LEGAL REPRESENTATIVE:	Woodcock Washburn Kurtz Mackiewicz & Norris LLP	
NUMBER OF CLAIMS:	54	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	11 Drawing Figure(s); 11 Drawing Page(s)	
LINE COUNT:	6923	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention generally relates to optoacoustic contrast agents and methods of diagnostic and therapeutic imaging using optoacoustic contrast agents.

DRWD FIG. 4 is an embodiment of a composition of the present invention where photoactive agents are incorporated in an oily **hydrophobic** mantle (1) in the vesicles, and where a gas phase (2) is incorporated in the interior of the vesicle.

DETD "Lipid" refers to a naturally-occurring, synthetic or semi-synthetic (i.e., modified natural) compound which is generally **amphipathic**. The lipids typically comprise a **hydrophilic** component and a

hydrophobic component. Suitable lipids include, for example, fatty acids, neutral fats, fluorinated lipids, phosphatides, oils, fluorinated oils, glycolipids, surface active agents. . . .

DETD . . . a compound that alters surface tension. Surface active agents include, for example, detergents, wetting agents, dispersing agents, foaming agents and **emulsifiers**. Preferable examples of surfactants are **hydrophobic** compounds, including phospholipids, oils, fluorinated oils and fluorosurfactants.

DETD "Amphiphilic moiety" or "amphiphile" refers to a synthetic, semi-synthetic (modified natural) or naturally-occurring compound having a water-soluble, **hydrophilic** portion and a water-insoluble, **hydrophobic** portion. Preferred amphiphilic compounds have a polar head group, for example, a phosphatidylcholine group, and one or more nonpolar, aliphatic. . . . "Perfluorinated amphiphilic moiety" refers to amphiphilic compounds in which all the hydrogen atoms have been replaced with a fluorine atom. "**Amphipathy**" refers to the simultaneous attraction and repulsion in a single molecule or ion containing one or more groups having an affinity for the phase or medium in which they are dissolved, **emulsified** and/or suspended, together with one or more groups that tend to be expelled from the involved phase or medium.

DETD . . . walls or membranes may be concentric or otherwise. The stabilizing compounds may be in the form of one or more **monolayers** or **bilayers**. In the case of more than one **monolayer** or **bilayer**, the **monolayers** or **bilayers** may be concentric. Stabilizing compounds may be used to form a **unilamellar** vesicle (comprised of one **monolayer** or **bilayer**), an **oligolamellar** vesicle (comprised of about two or about three **monolayers** or **bilayers**) or a **multilamellar** vesicle (comprised of more than about three **monolayers** or **bilayers**). The walls or membranes of vesicles may be substantially solid (uniform), or they may be porous or semi-porous. The internal. . . .

DETD "Liposome" refers to a generally spherical or spheroidal cluster or aggregate of **amphipathic** compounds, including lipid compounds, typically in the form of one or more concentric **layers**, for example, **bilayers**. They may also be referred to as lipid vesicles or lipid microspheres. The liposomes may be formulated, for example, from. . . .

DETD "**Micelle**" refers to **colloidal** entities formulated from lipids. In preferred embodiments, **micelles** comprise a **monolayer**, **bilayer**, or hexagonal H II phase structure.

DETD "**Emulsion**" refers to a mixture of two or more generally immiscible liquids, and is generally in the form of a **colloid**. The mixture may be of lipids, for example, which may be homogeneously or heterogeneously dispersed throughout the **emulsion**.

DETD Alternatively, the lipids may be aggregated in the form of, for example, clusters or **layers**, including **monolayers** or **bilayers**.

DETD . . . phase structure" refers to a generally tubular aggregation of lipids in liquid media, for example, aqueous media, in which the **hydrophilic** portion(s) of the lipids generally face inwardly in association with an aqueous liquid environment inside the tube.

DETD The **hydrophobic** portion(s) of the lipids generally radiate outwardly and the complex assumes the shape of a hexagonal tube. A plurality of. . . .

DETD . . . comprise a stabilizing material and a photoactive agent. "Optoacoustic contrast agent" also refers, for example, to delivery vehicles, vesicles, liposomes, **micelles**, **emulsions**, suspensions, dispersions, aerogels, clathrates, hexagonal H II phase

structures and the like. Such contrast agents are capable of providing an. . .

- DETD . . . a photoactive agent, a bioactive agent and/or a targeting ligand. Suitable delivery vehicles include, for example, stabilizing materials, vesicles, liposomes, **micelles**, aerogels, clathrates, gas and/or gaseous precursor filled vesicles, **emulsions**, suspensions, dispersions, hexagonal H II phase structures, cochleates and the like.
- DETD . . . containing the photoactive agents, gases, gaseous precursors, liquids, bioactive agents and/or targeting ligands described herein, including, for example, mixtures, suspensions, **emulsions**, dispersions, vesicles, or the like. The improved stability involves, for example, the maintenance of a relatively balanced condition, and may. . . maintained entrapped until release is desired. Exemplary stabilizing materials include lipids, proteins, polymers, carbohydrates and surfactants. The resulting mixture, suspension, **emulsion** or the like may comprise walls (e.g., films, membranes and the like) around the photoactive agent, targeting ligand, bioactive agent, . . .
- DETD "**Hydrophilic** interaction" refers to molecules or portions of molecules which may substantially bind with, absorb and/or dissolve in water. This may. . .
- DETD "**Hydrophobic** interaction" refers to molecules or portions of molecules which do not substantially bind with, absorb and/or dissolve in water. "Biocompatible". . .
- DETD . . . refers to the incorporation of photoactive agents, bioactive agents and/or targeting ligands in stabilizing compositions of the present invention, including **emulsions**, suspensions, vesicles and the like. Photoactive agents, bioactive agents and/or targeting ligands can be combined with the stabilizing compositions in. . . within the internal void of the vesicles. Photoactive agents, bioactive agents and/or targeting ligands may also be integrated within the **layer(s)** or wall(s) of the vesicle, for example, by being interspersed among stabilizing materials which form or are contained within the vesicle **layer(s)** or wall(s). In addition, photoactive agents, bioactive agents and/or targeting ligands may be located on the surface of vesicles or. . . bioactive agents and/or targeting ligands may be concurrently entrapped within the internal void of the vesicle and/or integrated within the **layer(s)** or wall(s) of the vesicles and/or located on the surface of vesicles or non-vesicular stabilizing materials. Targeting ligands are preferably. . .
- DETD . . . a vesicular membrane(s). Optically active contrast agents that are also highly acoustically active may be produced by incorporating lipophilic, preferably **amphipathic** photoactive agents into the lipid compositions.
- DETD . . . example of an optoacoustic contrast agent of the present invention with an internal oil phase (1). A high concentration of **hydrophobic** photoactive agents (e.g., A-I) can be loaded into the interior of the oil phase within the vesicle by virtue of. . . an optoacoustic contrast agent with a higher concentration of photoactive agent than lipid-based compositions which may have only a thin **layer** (e.g., **monolayer** or **bilayer**) of lipid surrounding a gas phase. Depending upon the solubility of the photoactive agents in the oil phase, it is. . .
- DETD . . . tissue specific targeting for the composition. The region for entrapment of photoactive agents (2) may be, for example, an oily **hydrophobic** region.
- DETD . . . hydroxyl groups, such as triglycerides of d-12-hydroxyoleic acid, including castor oil and ergot oil. Polymerization may be designed to include **hydrophilic** substituents such as carboxyl or

hydroxyl groups, to enhance dispersability so that the backbone residue resulting from biodegradation is water. . . .

DETD . . . surface tension on the vesicle membrane or skin. It is possible that propylene glycol can also function as an additional **layer** that may coat the membrane or skin of the vesicle, thus providing additional stabilization. The surfactants described in U.S. Pat. . . .

DETD Compounds used to make mixed **micelle** systems may be used as basic or auxiliary stabilizing materials, and include, for example, sodium dodecyl sulfate, cetylammonium halides, cetylalkylammonium. . . .

DETD . . . of vesicles to rupture by fusing together. Thus, the negatively charged lipids may act to establish a uniform negatively charged **layer** on the outer surface of the vesicle, which will be repulsed by a similarly charged outer **layer** on other vesicles which are proximate thereto. In this way, the vesicles may be less prone to come into touching. . . .

DETD . . . 2; X.sub.3 is a direct bond or --O--; M is P or S; Z is hydrogen, the residue of a **hydrophilic** polymer, a saccharide residue or --N(R.sub.6).sub.r, where r is 2 or 3; each R, is independently an alkyl group of. . . . each R.sub.6 is independently hydrogen, an alkyl group of 1 to about 8 carbon atoms or a residue of a **hydrophilic** polymer; provided that at least one of x, y and z is 1, at least one of R.sub.1 is a. . . .

DETD Z is hydrogen atom, the residue of a **hydrophilic** polymer, a saccharide residue or --N(R.sub.6).sub.r, where r is 2 or 3. In preferred embodiments, Z is --N(R.sub.6).sub.r.

DETD R.sub.6 is a hydrogen atom, an alkyl group of 1 to about 8 carbon atoms or a residue of a **hydrophilic** polymer. Preferably, R.sub.6 is a hydrogen atom or an alkyl group of 1 to about 4 carbon atoms. More preferably,

DETD Z and R.sub.6 in the definition of Z in formula (IV), can be the residue of a **hydrophilic** polymer. Exemplary polymers from which Z and/or R.sub.6 can be derived include polymers in which the repeating units contain one. . . .

DETD . . . 5,000 and PEG 8,000, which have molecular weights of 2,000, 5,000 and 8,000, respectively, being even more preferred. Other suitable **hydrophilic** polymers, in addition to those exemplified above, will be readily apparent to one skilled in the art based on the. . . .

DETD In addition to residues of **hydrophilic** polymers, Z in formula (IV) can be a saccharide residue. Exemplary saccharides from which Z can be derived include, for. . . .

DETD . . . disrupted vesicles. Fluorine can also be introduced into stabilizing materials and/or vesicles using other methods, such as sonication, spray-drying or **emulsification** techniques.

DETD . . . situated at the interface between the gas and the membrane or wall surface of the vesicle. Thus, an additional stabilizing **layer** of fluorinated liquid compound may be formed on the internal surface of the stabilizing composition which may also prevent any. . . .

DETD . . . nonionic or zwitterionic lipid, (2) a negatively charged lipid, and (3) a lipid bearing a stabilizing material, for example, a **hydrophilic** polymer. Preferably, the amount of the negatively charged lipid will be greater than about 1 mole % of the total lipid present, and the amount of lipid bearing a **hydrophilic** polymer will be greater than about 1 mole % of the total lipid present. Exemplary and preferred negatively charged lipids include phosphatidic acids. The lipid bearing a **hydrophilic** polymer will desirably be a lipid covalently linked to the polymer, and the polymer will preferably have a weight average molecular weight of from about 400 to about 100,000. Suitable **hydrophilic** polymers are preferably selected from the group consisting of polyethylene glycol (PEG),

polypropylene glycol, polyvinyl alcohol, and polyvinyl pyrrolidone and. . . or other phospholipids, with a covalent bond including, for example, amide, ester, ether, thioester, thioamide or disulfide bonds. Where the **hydrophilic** polymer is PEG, a lipid bearing such a polymer will be said to be "pegylated." In preferred form, the lipid bearing a **hydrophilic** polymer may be DPPE-PEG, including, for example, DPPE-PEG5000, which refers to DPPE having a polyethylene glycol polymer of a mean. . .

DETD . . . and 100,000; and di- and trihydroxy alkanes and their polymers, preferably with molecular weight ranges between 200 and 50,000; (ii) **emulsifying** and/or solubilizing agents including, for example, acacia, cholesterol, diethanolamine, glyceryl monostearate, lanolin alcohols, lecithin, mono- and di-glycerides, mono-ethanolamine, oleic acid, . . . propylene glycol monostearate, sodium lauryl sulfate, sodium stearate, sorbitan mono-laurate, sorbitan mono-oleate, sorbitan mono-palmitate, sorbitan monostearate, stearic acid, trolamine, and **emulsifying** wax; (iii) suspending and/or viscosity-increasing agents, including, for example, acacia, agar, alginic acid, aluminum mono-stearate, bentonite, magma, carbomer 934P, carboxymethyl-cellulose, . . .

DETD . . . vesicles are desirably formulated in an aqueous environment which can induce the stabilizing material (e.g., a lipid because of its **hydrophobic-hydrophilic** nature) to form vesicles, which may be the most stable configuration which can be achieved in such an environment. The. . .

DETD . . . gaseous precursors may be incorporated, for example, in stabilizing materials in which the stabilizing materials are aggregated randomly, such as **emulsions**, dispersions or suspensions, as well as in vesicles, including vesicles such as cochleates, **micelles** and liposomes. Incorporation of the gases and/or gaseous precursors in the stabilizing materials and/or compositions may be achieved by a. . .

DETD . . . liquid to gaseous states at relatively close to normal body temperature (37° C.) or below, and the size of the **emulsified** droplets that would be required to form a vesicle of a maximum size of 10 μ m.

DETD TABLE 1

Physical Characteristics of Gaseous Precursors and
Diameter of **Emulsified** Droplet to Form a 10 μ m Vesicle
Diameter (μ m) of
Mole- Boiling **emulsified** droplet
cular Point to make
Compound Weight (° C.) Density 10 μ m vesicle

perfluoropentane

288.04	28.5	1.7326
		2.9

1-fluorobutane 76.11 32.5. . .

DETD . . . be used as targeting ligands. Additionally, cholesterol may be used to target the endothelial cells and localize the stabilizing materials, **emulsions**, vesicles and the like, to regions of atherosclerotic plaque. In embodiments involving the use of cholesterol as a targeting ligand, . . .

DETD . . . or 2-azetidinone-4-carboxylic acid; B is serine, glycine, valine, alanine, threonine or β -alanine; C is an amino acid group having a **hydrophobic** functional group; and D is hydroxy or amino; wherein R.sub.1 is hydrogen, --(CH.sub.2).sub.p CH.sub.3 or --CO--(CH.sub.2).sub.p CH.sub.3 ; R.sub.2 is. . .

DETD where A is arotic acid or hydroorotic acid; B is an amino acid; C is an

amino acid having a **hydrophobic** functional group; and D is hydroxy or amino. In the above compounds, amino acids having **hydrophobic** functional groups in the definition of "C" include, for example, tryptophan and phenylalanine.

DETD . . . ligand is preferably covalently bound to the surface of the stabilizing material or vesicle by a spacer including, for example, **hydrophilic** polymers, such as the **hydrophilic** polymers described herein, preferably polyethylene glycol. Preferred molecular weights of the polymers are from 1000 da to 10,000 da, with. . .

DETD . . . be apparent to one skilled in the art in view of the present disclosure. Preferably, the linking group comprises a **hydrophilic** polymer. Suitable **hydrophilic** polymers include, for example, polyalkyleneoxides such as, for example, polyethylene glycol (PEG) and polypropylene glycol (PPG), polyvinylpyrrolidones, polyvinylmethylethers, polyacrylamides, such. . . polyhydroxypropyl methacrylates, polymethyl-oxazolines, polyethyloxazolines, polyhydroxyethyl-oxazolines, polyhydroxypropyl-oxazolines, polyvinyl alcohols, polyphosphazenes, poly(hydroxyalkylcarboxylic acids), polyoxazolidines, polyaspartamide, and polymers of sialic acid (polysialics). The **hydrophilic** polymers are preferably selected from the group consisting of PEG, PPG, polyvinylalcohol and polyvinylpyrrolidone and copolymers thereof, with PEG and. . .

DETD . . . ligand. Thus, using the example DPPE-PEG, such as, for example, DPPE-PEG5000, the aforementioned conjugate may be represented as DPPE-PEG5000-TL. The **hydrophilic** polymer used as a linking group is preferably a bifunctional polymer, for example, bifunctional PEG, such as diamino-PEG. In this. . . to a lipid compound, and is bound at the free end to the targeting ligand via an amide linkage. A **hydrophilic** polymer, for example, PEG, substituted with a terminal carboxylate group on one end and a terminal amino group on the other end, may also be used. These latter bifunctional **hydrophilic** polymer may be preferred since they possess various similarities to amino acids.

DETD . . . used to link the targeting ligand to the lipid when utilizing linker groups having two unique terminal functional groups. Bifunctional **hydrophilic** polymers, and especially bifunctional PEGs, may be synthesized using standard organic synthetic methodologies. In addition, many of these materials are. . .

DETD . . . for example, hydroxy, thio and amine groups, which can react with a carboxylic acid or carboxylic acid derivative of the **hydrophilic** polymeric linker using suitable coupling conditions which would be apparent to one of ordinary skill in the art in view. . .

DETD . . . on a backbone of a polymer which is included in the vesicles, may be coupled to amine groups on a **hydrophilic** linking polymer by forming a Schiff's base, for example, by using coupling agents, such as glutaraldehyde. An example of this. . . may be activated as described above. The activated amine groups can be used, in turn, to couple to a functionalized **hydrophilic** polymer, such as, for example, α -amino- ω -hydroxy-PEG in which the ω -hydroxy group has been protected with a carbonate group. After the. . .

DETD . . . of a dialdehyde, for example, glutaraldehyde as described above, to form a Schiff's base. After linking the DPPE to the **hydrophilic** polymer and the targeting ligand, the vesicles may be formulated utilizing the procedures described herein.

DETD . . . procedures, the polymer or terminus of the lipid, for example, phosphatidylglycerol or phosphatidylethanolamine, is preferably activated and coupled to the **hydrophilic** polymeric linker, the

terminus of which has been blocked in a suitable manner. As an example of this strategy, α -amino- ω -carboxy-PEG4000. . .

DETD The free end of the **hydrophilic** spacer, such as polyethylene glycol ethylamine, which contains a reactive group, such as an amine or hydroxyl group, may be. . . will be evaporated to dryness under argon. Excess unreacted SMPB and major by products will be removed by preparative thin **layer** chromatography (TLC, silica gel developed with 50% acetone in chloroform). The upper portion of the lipid band can be extracted. . .

DETD The targeted compounds of the present invention are incorporated in compositions which may be used to form targeted **emulsions** and/or targeted vesicles, including, for example, targeted **emulsions**, targeted **micelles**, targeted liposomes, targeted albumin coated microspheres, targeted polymer coated microspheres, targeted cochleates and the like. The targeting ligand which is. . .

DETD . . . network, and the like. Non-covalent bonds are preferably selected from the group consisting of ionic interaction, dipole--dipole interaction, hydrogen bonds, **hydrophilic** interactions, van der Waal's forces, and any combinations thereof. Non-covalent interactions may be employed to bind the targeting ligand to. . .

DETD wherein L is a lipid, protein, polymer, carbohydrate, surfactant, photoactive agent or the like; P is a **hydrophilic** polymer; and T is a targeting ligand.

DETD In the above compounds, P is a **hydrophilic** polymer. Preferably, P is a **hydrophilic** polymer selected from the group consisting of polyalkyleneoxides, polyvinyl alcohol, polyvinylpyrrolidones, polyacrylamides, polymethacrylamides, polyphosphazenes, phosphazene, poly(hydroxyalkylcarboxylic acids) and polyoxazolidines. More. . .

DETD . . . --; each n is, independently, 0 or 1; Y is hydrogen or a pharmaceutically acceptable counter ion; Z is a **hydrophilic** polymer; Q is a targeting ligand or a precursor to a targeting ligand; each R.sub.1 is independently an alkyl group. . .

DETD In the above formula, Z is a **hydrophilic** polymer. Preferably, Z is selected from the group consisting of polyalkyleneoxides, polyvinyl alcohol, polyvinylpyrrolidones, polyacrylamides, polymethacrylamides, polyphosphazenes, poly(hydroxyalkyl-carboxylic acids) and. . . polyethylene glycol and polypropylene glycol, with polyethylene glycol being still more preferred. In certain other preferred embodiments, Z is a **hydrophilic** polymer other than polyalkylene-oxides, including polyethylene glycol and polypropylene glycol. The molecular weight of Z may vary, depending, for example,. . .

DETD A wide variety of methods are available for the preparation of the stabilizing materials, including vesicles, such as **micelles** and/or liposomes. Included among these methods are, for example, shaking, drying, gas-installation and spray drying. Suitable methods for preparing vesicle. . .

DETD **Micelles** may be prepared using any one of a variety of conventional **micellar** preparatory methods which will be apparent to one skilled in the art. These methods typically involve suspension of the stabilizing. . . discussed, for example, in Canfield et al, Methods in Enzymology, 189:418 (1990); El-Gorab et al, Biochem. Biophys. Acta, 306:58 (1973); **Colloidal** Surfaciant, Shinoda, K., Nakagana, Tamamushi and Isejura, Academic Press, NY (1963) (especially "The Formation of **Micelles**," Shinoda, Chapter 1, pp. 1-88); Catalysis in **Micellar** and Macromolecular Systems, Fendler and Fendler, Academic Press, NY (1975). The disclosures of each of the foregoing publications are hereby. . .

DETD In liposomes, the lipid compound(s) may be in the form of a

monolayer or bilayer, and the monolayer or bilayer lipids may be used to form one or more monolayers or bilayers. In the case of more than one monolayer or bilayer, the monolayers or bilayers are generally concentric. Thus, lipids may be used to form unilamellar liposomes (comprised of one monolayer or bilayer), oligolamellar liposomes (comprised of two or three monolayers or bilayers) or multilamellar liposomes (comprised of more than three monolayers or bilayers).

DETD . . . solvent dialysis, French press, extrusion (with or without freeze-thaw), reverse phase evaporation, simple freeze-thaw, sonication, chelate dialysis, homogenization, solvent infusion, microemulsification, spontaneous formation, solvent vaporization, solvent dialysis, French pressure cell technique, controlled detergent dialysis, and others, each involving the preparation of. . . Praeparate GMBH & Co., Seefeld, Oberay Germany), a Silamat Plus (Vivadent, Lechtenstein), or a Vibros (Quayle Dental, Sussex, England). Conventional microemulsification equipment, such as a Microfluidizer.TM. (Microfluidics, Woburn, Mass.) may also be used.

DETD . . . to liquid crystalline phase transition temperature of the lipids. This phase transition temperature is the temperature at which a lipid bilayer will convert from a gel state to a liquid crystalline state. See, for example, Chapman et al, J. Biol. Chem., . . . crystalline state phase transition temperatures tend to have enhanced impermeability at any given temperature. See Marsh, CRC Handbook of Lipid Bilayers (CRC Press, Boca Raton, Fla. 1990), at p. 139 (the disclosure of which is hereby incorporated by reference herein in.

DETD . . . No. 08/307,305, filed Sep. 16, 1994, the disclosures of each of which are incorporated herein by reference in their entirety. Emulsion processes may also be employed in the preparation of compositions in accordance with the present invention. Such emulsification processes are described, for example, in Quay, U.S. Pat. Nos. 5,558,094, 5,558,853, 5,558,854, and 5,573,751, the disclosures of each of.

DETD Microemulsification is a common method of preparing an emulsion of a foam precursor. Temperature increases and/or lowered pressures will cause foaming as gas bubbles form in the liquid. As.

DETD The size of gas filled vesicles can be adjusted, if desired, by a variety of procedures, including, for example, microemulsification, vortexing, extrusion, filtration, sonication, homogenization, repeated freezing and thawing cycles, extrusion under pressure through pores of defined size, and similar. .

DETD . . . gas is incorporated, for example, into a vesicle. For gaseous precursors having low temperature boiling points, liquid precursors may be emulsified using a microfluidizer device chilled to a low temperature. The boiling points may also be depressed using solvents in liquid. . .

DETD . . . a temperature below the liquid-gaseous phase transition temperature of the respective gaseous precursor. As the temperature is increased, and an emulsion is formed between the gaseous precursor and liquid solution, the gaseous precursor undergoes transition from the liquid to the gaseous. . .

DETD As a further embodiment of this invention, by pre-forming the gaseous precursor in the liquid state into an aqueous emulsion, the maximum size of the vesicle may be estimated by using the ideal gas law,

once the transition to the . . . due to diffusion into the liquid, which is generally aqueous in nature. Hence, from a known liquid volume in the **emulsion**, one would be able to predict an upper limit to the size of the gas filled vesicle.

DETD . . . to form a vesicle with an upper limit of 10 μm . Finally, using equation (C), a mixture, for example, an **emulsion** containing droplets with a radius of 0.0272 μm or a corresponding diameter of 0.0544 μm , is formed to make a . . .

DETD An **emulsion** of this particular size could be easily achieved by the use of an appropriately sized filter. In addition, as seen. . .

DETD . . . be performed during in vivo administration of the vesicles such that a filter of about 0.22 μm is employed; (b) **microemulsification** whereby an aqueous mixture of gaseous precursor is **emulsified** by agitation and heated to form, for example, vesicles prior to administration to a patient; (c) heating a gaseous precursor. . .

DETD . . . as about 30 minutes, preferably within about 20 minutes, and more preferably within about 10 minutes. The shaking may involve **microemulsifying**, microfluidizing, swirling (such as by vortexing), side-to-side, or up and down motion. In the case of the addition of gaseous. . .

DETD . . . prepared as described above in which the compositions also comprise photoactive agents, bioactive agents and/or targeting ligands. Thus, for example, **micelles** can be prepared in the presence of a photoactive agent, bioactive agent and/or targeting ligand. In connection with lipid compositions. . .

DETD . . . temperature below the liquid-gaseous phase transition temperature of the respective gaseous precursor. As the temperature is then exceeded, and an **emulsion** is formed between the gaseous precursor and liquid solution, the gaseous precursor undergoes transition from the liquid to the gaseous. . . entrapped fluorobutane gas results. As an additional example, the gaseous precursor fluorobutane, can be suspended in an aqueous suspension containing **emulsifying** and stabilizing agents such as glycerol or propylene glycol and vortexed on a commercial vortexer. Vortexing is commenced at a . . . transition temperature from the liquid to gaseous state. In so doing, the precursor converts to the gaseous state during the **microemulsification** process. In the presence of the appropriate stabilizing agents, surprisingly stable gas filled vesicles and photoactive agents, bioactive agents and/or. . .

DETD . . . that a solvent, a surfactant, and a photoactive agent, a targeting ligand and/or bioactive agent are combined to form an **emulsion** in the form of a random aggregate. In the case of spray drying, the **emulsion**, or **colloidal** suspension, is placed into association with a blowing agent such as methylene chloride, for example. Each of the ingredients of. . . as a phospholipid or a fluorosurfactant, within aqueous or organic media, the former being preferred. Additionally, some nonpolar photoactive agent **emulsions** may contain an oil to effect solubilization. As the suspension or **emulsion** is then spray dried, the photoactive agent and/or bioactive agent dries and the blowing agent and solvent are removed tending. . .

DETD . . . lyophilization. A bulk quantity of the composition of the present invention may be prepared with a ball mill or a **colloid** mill device. The appropriate sized crystalline particles are prepared, generally under 10 μm , preferably under 5 μm and still more. . .

DETD . . . a patient's lungs. For pulmonary applications, dried or lyophilized powdered compositions may be administered via inhaler. Aqueous suspensions of liposomes, **micelles** or other vesicles, preferably gas/gaseous precursor filled, may be administered via

nebulization. The compositions of the present invention are lighter.

DETD . . . of the vesicles can be adjusted, if desired, by procedures known to one skilled in the art, such as shaking, **microemulsification**, vortexing, filtration, repeated freezing and thawing cycles, extrusion, extrusion under pressure through pores of a defined size, sonication, homogenization, the.

DETD Perfluoropropane encapsulated lipid **bilayers** were formed with a lipid formulation comprising 5 mg/ml of a mixture comprising 82 mole % dipalmitoylphosphatidylcholine, 10 mole % . . . Lipids, Alabaster, Ala.) in a vehicle comprising 8:1:1 of v:v:v normal saline:propylene glycol:glycerol, yielding a foam and a lower vehicle **layer** that was predominantly devoid of any particulate. To this mixture was added 1 mg/ml of dipalmitoylphosphatidylethanol-amine derivatized with lissamine rhodamine.

DETD . . . Capmix for two minutes at 4,500 rpm. Variations of the vehicle yielded varying degrees of clarity to the lower vehicle **layer**. Prior to filtration, the gas-filled microspheres were sized on a Particle Sizing SYStems Model 770 optical sizer (Particle Sizing Systems, . . .

DETD . . . minutes at 50° C. then transferred into a container with 200 mls normal saline plus 1% w/v Pluronic F-65 and **emulsified** with a Microfluidizer (10+) at 16,000 psi while the temperature was maintained at 50° C. The material was then subdivided.

DETD . . . poured into ice water and neutralized with 10% HCl to a pH of about 3 or less. The lower organic **layer** was removed using a separatory funnel and washed three times with water. The organic **layer** was collected and dried (NaSO.sub.4). Filtration and concentration in vacuo yielded 0.34 g of a white solid of 3- ω -carboxy-polyethyleneglycol-imino-succinat-1,2-dipalmitoyl-sn-glycerol (DPGS- ω -carboxy-PEG).

DETD . . . poured into ice water and neutralized with 10% HCl to a pH of about 3 or less. The lower organic **layer** was removed using a separatory funnel and washed three times with water. The organic **layer** was collected and dried (NaSO.sub.4). Filtration and concentration in vacuo yielded 0.34 g of a white solid of 3- ω -carboxypolyethyleneglycol-imino-succinat-1,2-dipalmitoyl-sn-glycerol (DPGS-6-carboxy-PEG).

IC [7]
ICM: A61K049-00
ICS: A61K049-22

IT 106-60-5, δ -Aminolevulinic acid 302-79-4, Retinoic acid 302-79-4D, Retinoic acid, derivs. 479-61-8 553-12-8, Protoporphyrin IX 574-93-6D, Phthalocyanine, derivs. 603-34-9D, Triphenylamine, derivs. 643-79-8, o-Phthaldialdehyde 917-23-7D, Tetraphenylporphine, sulfonated derivs. 1075-06-5, Phenylglyoxal monohydrate 1210-12-4, 9-Anthrone 2321-07-5D, Fluorescein, derivs. 3599-32-4, Indocyanine green 5143-18-0 7149-49-7, Naphthalene-2,3-dicarboxaldehyde 12713-07-4D, Verdin, derivs. 12778-00-6, Mesochlorin 13558-31-1D, derivs. 14325-05-4, Tin protoporphyrin 14459-29-1, Hematoporphyrin 19660-77-6, Chlorin e6 19660-77-6D, Chlorin e6, mono-L-aspartyl derivative 23627-89-6D, Naphthalocyanine, derivs. 25440-13-5 26038-83-5, 4-Heptadecyl-7-hydroxycoumarin 41085-99-8 41387-42-2 60415-70-5D, 21H,23H-Porphin-5(22H)-one, derivs. 61494-52-8, 1-Pyrenesulfonyl chloride 62796-29-6, Lissamine rhodamine B sulfonyl chloride 62888-19-1, Bonellin 65603-18-1 65603-19-2, Octadecyl rhodamine B chloride 68335-15-9, Photofrin 72467-67-5 72535-39-8 73024-99-4, 12-(9-Anthroyloxy)oleic acid 75168-11-5 76081-97-5, Cholesteryl 1-pyrenebutyrate 78949-95-8 88235-25-0 88478-07-3 95864-17-8 96886-70-3 97850-83-4, Cholesteryl

1-pyrenedecanoate 99128-91-3, Octaethylpurpurin 100572-96-1D,
 Porphycene, compds. 105344-74-9 113471-15-1 114041-00-8
 114494-17-6 114586-25-3 115645-42-6 123738-53-4 123940-54-5,
 Hypocrellin B 128146-77-0 134020-79-4D, Sapphyrin, derivs.
 135615-37-1D, Rubyrin, derivs. 138026-68-3 147662-88-2,
 2-Dodecylresorufin 151736-99-1 151892-94-3 186833-02-3
 216434-81-0 217187-10-5 227936-56-3D 224-1,2,5-
 Oxatellurazole, d
 (as photoactive *see structure* trast agents and methods for
 their use in ul *p. 35* ging)

=> FIL STNGUIDE

FILE 'STNGUIDE' ENTERED	004
USE IS SUBJECT TO THE T	REEMENT
COPYRIGHT (C) 2004 AMER	JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE	

FILE CONTAINS CURRENT INFORMATION.
 LAST RELOADED: May 21, 2004 (20040521/UP).

=>

4/4

Mohamed 09/916,028 Inventors

05/27/2004

=> fil zcaplus

FILE 'ZCAPLUS' ENTERED AT 12:49:02 ON 27 MAY 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS is strictly prohibited.

FILE COVERS 1907 - 27 May 2004 VOL 140 ISS 22
FILE LAST UPDATED: 26 May 2004 (20040526/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 12:49:06 ON 27 MAY 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 May 2004 VOL 140 ISS 22
FILE LAST UPDATED: 26 May 2004 (20040526/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> fil biosis

FILE 'BIOSIS' ENTERED AT 12:49:09 ON 27 MAY 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE COVERS 1969 TO DATE.
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 26 May 2004 (20040526/ED)

FILE RELOADED: 19 October 2003.

=> FIL STNGUIDE

FILE 'STNGUIDE' ENTERED AT 12:49:14 ON 27 MAY 2004
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: May 21, 2004 (20040521/UP).

=> d que 1124

L121 134 SEA FILE=HCAPLUS ABB=ON PLU=ON LU/AU OR "LU D"/AU OR "LU D
R"/AU OR "LU D ROBERT"/AU OR ("LU DONGHAO"/AU OR "LU DONGHAO
R"/AU OR "LU DONGHAO ROBERT"/AU)
L122 10 SEA FILE=HCAPLUS ABB=ON PLU=ON ("SHAWER M"/AU OR "SHAWER M
B"/AU OR "SHAWER M F"/AU OR "SHAWER MOHANNAD"/AU)
L124 3 SEA FILE=HCAPLUS ABB=ON PLU=ON L121 AND L122

=> d que 1130

L83 168 SEA FILE=BIOSIS ABB=ON PLU=ON ?CHOLEST? (L) (?BORO? OR
?BORIC? OR ?BORAN? OR ?BORAX?)
L84 633075 SEA FILE=BIOSIS ABB=ON PLU=ON (?COLLOID? OR ?EMULS? OR
?LAYER? OR ?CORE? OR ?AMPHIPATH? OR ?HYDROPHOB? OR ?HYDROPHIL?
OR ?LAMEL? OR ?MICELL?)
L86 28 SEA FILE=BIOSIS ABB=ON PLU=ON L84 AND L83
L87 10 SEA FILE=BIOSIS ABB=ON PLU=ON L86 AND (TETRAPHENYLBORON OR
BORON NEUTRON-CAPTURE OR BORON NEUTRON CAPTURE OR MURINE
TUMORS OR XENOGRAFTS OR BNCT OR VLDL OR CHOLESTERYL CARBORANE)/
TI
L88 31 SEA FILE=BIOSIS ABB=ON PLU=ON L83 AND (?DRUG? OR ?RADIOTHER?
OR ?IMAG? OR ?PHARMACEUT?)
L89 25 SEA FILE=BIOSIS ABB=ON PLU=ON L88 NOT L86
L90 6 SEA FILE=BIOSIS ABB=ON PLU=ON L89 AND (BRATTLEBORO OR DRUG
DELIVERY OR BORON NEUTRON CAPTURE)/TI
L91 5 SEA FILE=BIOSIS ABB=ON PLU=ON L90 NOT CORTICAL/TI
L93 15 SEA FILE=BIOSIS ABB=ON PLU=ON L87 OR L91
L120 13 SEA FILE=BIOSIS ABB=ON PLU=ON L93 NOT (BRATTLEBORO OR
TETRAPHENYLBORON)/TI
L127 333 SEA FILE=BIOSIS ABB=ON PLU=ON LU/AU OR "LU D"/AU OR ("LU D
R"/AU OR "LU D ROBERT"/AU) OR "LU DONGHAO ROBERT"/AU
L128 38 SEA FILE=BIOSIS ABB=ON PLU=ON ("SHAWER M"/AU OR "SHAWER M
B"/AU OR "SHAWER M F"/AU OR "SHAWER MOHANNAD"/AU) OR ("SHAWER
M"/AU OR "SHAWER M B"/AU OR "SHAWER M F"/AU OR "SHAWER
MOHANNAD"/AU)
L129 2 SEA FILE=BIOSIS ABB=ON PLU=ON L127 AND L128
L130 1 SEA FILE=BIOSIS ABB=ON PLU=ON L129 NOT L120

=> dup rem 1124 1130

FILE 'HCAPLUS' ENTERED AT 12:49:41 ON 27 MAY 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 12:49:41 ON 27 MAY 2004

COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC. (R)

PROCESSING COMPLETED FOR L124

PROCESSING COMPLETED FOR L130

L132 3 DUP REM L124 L130 (1 DUPLICATE REMOVED)

ANSWERS '1-3' FROM FILE HCAPLUS

=> d 1b1b abs 1132 1-3

L132 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2003:316317 HCAPLUS

139:369467

TITLE:

In vitro gene transfection in human glioma cells using
a novel and less cytotoxic artificial lipoprotein
delivery system

AUTHOR(S):

Pan, Guangliang; Shaver, Mohammad; Ole,
Svein; Lu, D. Robert

CORPORATE SOURCE:

College of Pharmacy, Department of Pharmaceutical and
Biomedical Sciences, University of Georgia, Athens,
GA, 30602, USA

SOURCE:

Pharmaceutical Research (2003), 20(5), 738-744
CODEN: PHREB; ISSN: 0724-8741

PUBLISHER:

Kluwer Academic/Plenum Publishers

DOCUMENT TYPE:

Journal

LANGUAGE:

English

AB

To develop and evaluate a novel artificial lipoprotein delivery system for
in vitro gene transfection in human glioma cells. Nanoemulsion was
formulated with similar lipid compns. present in natural lipoproteins.

The oil phase of nanoemulsion was composed of triolein (70%), egg
phosphatidylcholine (22.7%), lysophosphatidylcholine (2.3%), cholesterol
oleate (3.0%), and cholesterol (2.0%). To replace the surface protein as

in natural lipoprotein, poly-L-lysine was modified to add palmitoyl chains
at a basic condition and was incorporated onto the nanoemulsion particles

through hydrophobic interaction. A model plasmid DNA, pSV- β -gal
containing a reporter gene for β -galactosidase was carried by the

nanoemulsion/poly-L-lysine particles. The charge variation of so-formed
complex was examined by agarose gel electrophoresis and zeta potential

measurement. In vitro transfection was conducted on human SF-767 glioma
cell line using this new system. After standard X-Gal staining, transfected

cells were observed under light microscope. The effect of chloroquine on the
transfection was examined and, finally, the cytotoxicity of this new system
was evaluated in comparison with com. lipofectamine gene transfection

system. The plasmid DNA was effectively carried by this artificial

lipoprotein delivery system and the reporter gene was expressed in the

glioma cells. Transfection efficiency was significantly increased by the

treatment of chloroquine, indicating that endocytosis possibly was the

major cellular uptake pathway. Compared to lipofectamine system, this new

delivery system demonstrated similar transfection efficiency but a much

lower cytotoxicity. In the experiment, the cell viability showed up to 75%

using this system compared to only 24% using lipofectamine system. A new

artificial lipoprotein delivery system was developed for in vitro gene

transfection in tumor cells. The new system showed similar transfection

efficiency but a much lower cytotoxicity compared with com. lipofectamine

system.

REFERENCE COUNT: 29

THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L132 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:431808 HCAPLUS

138:192980

TITLE:

VLDL-resembling phospholipid-submicron emulsion for

cholesterol-based drug targeting
Shawer, Mohannad; Greenspan, Phillip; Ole,
Svein; Lu, D. Robert
Department of Pharmaceutical and Biomedical Sciences,
College of Pharmacy, University of Georgia, Athens,
GA, 30602, USA
Journal of Pharmaceutical Sciences (2002), 91(6),
1405-1413
CODEN: JPSABF; ISSN: 0022-3549
Wiley-Liss, Inc.
PUBLISHER:
DOCUMENT TYPE:
JOURNAL
LANGUAGE:
English
AB The objective of the current study was to develop and evaluate
VLDL-resembling phospholipid-submicron emulsion (PSME) as a carrier system
for new cholesterol-based compounds for targeted delivery to cancer cells.
BCH, a boronated cholesterol compound, was originally developed in our
laboratory
to mimic the cholesterol esters present in the LDL and to follow a similar
pathway of cholesterol transport into the rapidly dividing cancer cells.
The VLDL-resembling system was then designed to solubilize BCH, facilitate
the interaction with LDL, and thus assist the BCH delivery to cancer
cells. BCH-containing PSME was prepared by sonication. Chemical compounds and
particle sizes of different PSME fractions were determined. The lipid structure
of PSME and location of BCH in the formulation were assessed based on
exptl. results. D. gradient ultracentrifugation fractionated the emulsion
into three particle-size populations with structures and compounds
resembling native VLDL. In vitro interaction between PSME and LDL was
evident by agarose electrophoresis, as both formed a single band with an
intermediate mobility. The transfer of BCH from PSME to LDL was also
observed in the presence of other serum components including serum proteins.
Cell culture data showed sufficient uptake of BCH in rat glioma cells
(> 50 μ g boron/g cells). In conclusion, this system has the capability
to incorporate the cholesterol-based compound, interact with native LDL, and
assist the delivery of this compound into cancer cells in vitro.
REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

AUTHOR(S):

Lu, D. R.; Ji, B.; Peacock, G.; Shawer, M.

CORPORATE SOURCE:

University of Georgia, Athens, GA, 30602, USA

SOURCE:

Proceedings of the International Symposium on
Controlled Release of Bioactive Materials (2000),PUBLISHER:
DOCUMENT TYPE:Controlled Release Society, Inc.
JOURNAL

LANGUAGE:

English

AB Cholesteryl 1,12-dicarba-closo-dodecaborane-1-carboxylate was prepd and

had good cellular uptake efficiency. The approach may be useful for
targeted boron drug delivery to brain tumor cells.

REFERENCE COUNT: 3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> FIL STNGUIDE

=> log h

Mohamed 09/916,028 Inventors

05/27/2004

searched by D. Arnold 571-272-2532

Page 5